

## CONTENTS


---

FRONTISPIECE—Allan H. Conney	x
INDUCTION OF DRUG-METABOLIZING ENZYMES: A PATH TO THE DISCOVERY OF MULTIPLE CYTOCHROMES P450, Allan H. Conney	1
PROTEIN FLEXIBILITY AND COMPUTER-AIDED DRUG DESIGN, Chung F. Wong and J. Andrew McCammon	31
RETINOID RECEPTORS AND THEIR COREGULATORS, Li-Na Wei	47
NOVEL PHARMACOLOGICAL APPROACHES TO MANAGE INTERSTITIAL LUNG FIBROSIS IN THE TWENTY-FIRST CENTURY, Shri N. Giri	73
NITRIC OXIDE—RELEASING DRUGS, Claudio Napoli and Louis J. Ignarro	97
2,5-HEXANDIONE-INDUCED TESTICULAR INJURY, Kim Boekelheide, Shawna L. Fleming, Theresa Allio, Michelle E. Embree-Ku, Susan J. Hall, Kamin J. Johnson, Eun Ji Kwon, Sutchin R. Patel, Reza J. Rasoulpour, Heidi A. Schoenfeld, and Stephanie Thompson	125
HUMAN EXTRAHEPATIC CYTOCHROMES P450: FUNCTION IN XENOBIOTIC METABOLISM AND TISSUE-SELECTIVE CHEMICAL TOXICITY IN THE RESPIRATORY AND GASTROINTESTINAL TRACTS, Xinxin Ding and Laurence S. Kaminsky	149
HORMESIS: THE DOSE-RESPONSE REVOLUTION, Edward J. Calabrese and Linda A. Baldwin	175
SIGNAL TRANSDUCTION—DIRECTED CANCER TREATMENTS, Edward A. Sausville, Yusri Elsayed, Manish Monga, and George Kim	199
REGULATORY MECHANISMS CONTROLLING GENE EXPRESSION MEDIATED BY THE ANTIOXIDANT RESPONSE ELEMENT, Truyen Nguyen, Philip J. Sherratt, and Cecil B. Pickett	233
MONOAMINE TRANSPORTERS: FROM GENES TO BEHAVIOR, Raul R. Gainetdinov and Marc G. Caron	261
GENETIC POLYMORPHISMS OF THE HUMAN <i>MDR1</i> DRUG TRANSPORTER, Matthias Schwab, Michel Eichelbaum, and Martin F. Fromm	285
ACTIVATION OF THE ARYL HYDROCARBON RECEPTOR BY STRUCTURALLY DIVERSE EXOGENOUS AND ENDOGENOUS CHEMICALS, Michael S. Denison, and Scott R. Nagy	309

TRAFFICKING OF NMDA RECEPTORS, <i>Robert J. Wenthold, Kate Prybylowski, Steve Standley, Nathalie Sans, and Ronald S. Petralia</i>	335
TELOMERE INHIBITION AND TELOMERE DISRUPTION AS PROCESSES FOR DRUG TARGETING, <i>Evonne M. Rezler, David J. Bearss, and Laurence H. Hurley</i>	359
PHARMACOLOGY AND PHYSIOLOGY OF HUMAN ADRENERGIC RECEPTOR POLYMORPHISMS, <i>Kersten M. Small, Dennis W. McGraw, and Stephen B. Liggett</i>	381
GENE THERAPY WITH VIRAL VECTORS, <i>Neeltje A. Kootstra and Inder M. Verma</i>	413
K <sup>+</sup> CHANNEL STRUCTURE-ACTIVITY RELATIONSHIPS AND MECHANISMS OF DRUG-INDUCED QT PROLONGATION, <i>Colleen E. Clancy, Junko Kurokawa, Michihiro Tateyama, Xander H.T. Wehrens, and Robert S. Kass</i>	441
COMPLEMENTARY AND ALTERNATIVE THERAPEUTICS: RIGOROUS RESEARCH IS NEEDED TO SUPPORT CLAIMS, <i>Jane F. Kinsel and Stephen E. Straus</i>	463
CHALLENGING DOGMA: THRESHOLDS FOR GENOTOXIC CARCINOGENS? THE CASE OF VINYL ACETATE, <i>J.G. Hengstler, M.S. Bogdanffy, H.M. Bolt, and F. Oesch</i>	485
THE CAENORHABDITIS ELEGANS DOPAMINERGIC SYSTEM: OPPORTUNITIES FOR INSIGHTS INTO DOPAMINE TRANSPORT AND NEURODEGENERATION, <i>Richard Nass and Randy D. Blakely</i>	521
ALZHEIMER'S DISEASE: MOLECULAR UNDERSTANDING PREDICTS AMYLOID-BASED THERAPEUTICS, <i>Dennis J. Selkoe and Dale Schenk</i>	545
PROGRESS TOWARD CLINICAL APPLICATION OF THE NITRIC OXIDE-RELEASING DIAZENIUMDIOLATES, <i>Larry K. Keefer</i>	585
INNATE IMMUNE RESPONSES TO MICROBIAL POISONS: DISCOVERY AND FUNCTION OF THE TOLL-LIKE RECEPTORS, <i>Bruce Beutler</i>	609
THE ROLE OF DRUG TRANSPORTERS AT THE BLOOD-BRAIN BARRIER, <i>A.G. de Boer, I.C.J. van der Sandt, and P.J. Gaillard</i>	629
INDEXES	
Subject Index	657
Cumulative Index of Contributing Authors, Volumes 39-43	697
Cumulative Index of Chapter Titles, Volumes 39-43	700

## ERRATA

An online log of corrections to *Annual Review of Pharmacology and Toxicology* chapters may be found at  
<http://pharmtox.annualreviews.org/errata.shtml>







## SUBJECT INDEX

---

- A**  
ABC transporter(s), 285–86  
  subfamily, 641  
Ab4D5, 205–6  
ACE-Inhibitors  
  See Angiotensin converting  
  enzyme (ACE) inhibitors  
Acetaldehyde  
  exposure of tissues to,  
  508–10  
  and exposure to vinyl  
  acetate, 507–8, 512  
Acetaminophen, 513–14  
  and cigarette smoking, 17  
  and CYP genes, 156  
  oxidative metabolism of,  
  18, 19  
  toxicity, 603  
Acetanilide, 6, 7  
Acetic acid  
  exposure of tissues to,  
  508–10  
  and exposure to vinyl  
  acetate, 507  
Acetone, 17  
2-Acetoxybenzoate  
  2-(2-nitroxy)-butyl ester  
  (NCX-4215), 103–4  
2-Acetoxybenzoate 2-(2-  
  nitroxy-methyl)-phenyl  
  ester (NCX-4016),  
  103–4  
Acetyl salicylic acid, 465  
2-Acetylaminofluorene  
  (2-AAF), 498–99, 513  
Acetylcholine, 107, 111  
  and Alzheimer's disease,  
  547  
  in *C. elegans*, 523  
Acetylcholinesterase  
  inhibitors  
    and Alzheimer's disease,  
    551  
AcOM-PYRRO/NO, 588,  
  589  
  and erectile dysfunction,  
  603  
Acrylonitrile  
  and carcinogenesis, 486  
Actinomycin D, 10  
Action potential duration  
  (APD), 443  
  and  $I_{Ks}$ , 450–51, 454  
  prolongation, 449, 452, 453  
Activating signal  
  cointegrator-2 (ASC2),  
  58  
Acute lymphoblastic  
  leukemia (ALL)  
  childhood, 298  
Acute respiratory distress  
  syndrome (ARDS), 601,  
  602  
Adaptor-protein 2 (AP-2),  
  634–35  
Adeno-associated viral  
  (AAV) vectors  
  development and  
  production, 415–16  
  and gene viruses, 414–17  
  and hemophilia B, 430  
  properties of, 431  
  structure and replication,  
  414–15  
  tropism and transduction,  
  416–17  
Adenosine deaminase (ADA)  
  deficiency  
  and gene therapy, 429–30  
Adenosine triphosphate  
  (ATP)  
  ATP-binding (ABC)  
    superfamily, 285–86  
  and BL-induced lung  
  fibrosis, 76–77, 87  
  and cytoplasmic dyneins,  
  133  
  and OSI-774, 203  
  site antagonist(s), 204  
    cancer treatments, 199,  
    208  
Adenoviral (Ad) vector(s)  
  Ad/AAV hybrid vectors,  
  427  
  Ad/retrovirus hybrid  
  vectors, 427  
  and adeno-associated viral  
  (AAV) vectors, 414–15,  
  416  
  a death in clinical trials  
  with, 430  
  development and  
  production, 424–26  
  and gene therapy, 414,  
  424–27  
  properties of, 431  
  in the testis, 140  
  tropism and transduction,  
  426–27  
Adenovirus  
  structure and replication,  
  424  
Adenylyl cyclase  
  and adrenergic receptor  
  polymorphisms (ARPs),  
  381, 384, 385, 386, 388,  
  389–90, 399, 401, 403,  
  404  
Adipose tissue  
  and  $\beta_3$  adrenergic receptor  
  (AR), 396, 397–98  
ADP-ribose  
  and BL-induced lung

- fibrosis, 76
- $\beta$ -Adrenergic receptor  
( $\beta$ -AR), 451–52  
reduced responsiveness to, 453
- Adrenergic receptor (AR)  
antagonists  
and erectile dysfunction, 113
- Adrenergic receptor  
polymorphisms (ARPs), 381–404  
 $\alpha_1$ , 398–99  
 $\beta_1$ , 382–87  
 $\beta_2$ , 388–96  
 $\beta_3$ , 396–98  
 $\alpha_2A$ , 399–400  
 $\alpha_2B$ , 400–2  
 $\alpha_2C$ , 402–4
- Adrenomedullin (AM)  
and P-glycoprotein, 640
- Adsorptive-mediated  
transport (AMT), 631
- Adverse  
toxicological concept of, 175
- Aflacoxin B1  
formamidopyrimidine  
(AFB1-FAPY), 492
- Aflatoxin B1 (AFB1), 13,  
155, 485, 486, 491–94,  
513  
activation of, 154  
hepatocarcinogen, 237, 238
- AIDS  
and the blood-brain barrier, 632
- Alanine, 39, 558
- Albuterol, 392, 393, 394
- Alcohol ingestion, 22
- Alcoholics  
and drug tolerance, 19–20
- Aldosterone  
renin-angiotensin-  
aldosterone pathway,  
107
- Alkylphospholipids (ALP)  
and cancer treatment, 199,  
212–13
- Allelopathy  
and hormones, 185
- 17-Allyl-amino-17-  
demethoxygeldanamycin  
(17AAG), 199, 205
- Alpha-tocopherol, 110, 111
- Alteration/deficiency in  
activation (Ada)  
transcription factor  
coregulators, 56–57
- Alternative medicine  
See Medicine(s),  
complementary and  
alternative
- Alzheimer's disease (AD),  
534, 545–76, 647  
amyloid hypothesis for,  
573–74  
and apolipoprotein (apo) E,  
633  
and blood-brain barrier  
functionality, 632, 635  
clinical diagnosis of,  
546–47  
clinical syndrome, 546  
current treatments, 551–52  
defining, 546–50  
familial, 549–50  
immunotherapy for,  
564–71, 573  
and melanotransferrin  
(MTf), 645  
neurotransmitter  
phenotype, 547–48  
and oxidative stress, 253  
and potential  
neuroprotective strategies,  
552  
and statins usage, 573
- Amino acid(s), 215  
deletion, 400–4  
and polymorphisms, 382,  
383  
position 15, 385  
position 16, 388  
position 27, 388  
position 49, 382–83, 386  
position 64, 396  
position 389, 383, 386  
position 399, 383  
position 402, 383  
position 404, 383  
position 418, 383  
position 492, 398  
positions 301–3, 401
- Aminoazo dye(s)  
and cigarette smoking, 17  
and hydrocarbons, 3–5, 22
- 4-Aminobiphenyl (4-ABP),  
499, 513
- $\gamma$ -Aminobutyric acid  
(GABA)  
in *C. elegans*, 523
- Aminoguanidine, 84
- Aminopyrine, 5, 6
- Amnesic symptoms  
and Alzheimer's disease,  
546
- AMP-dependent protein  
kinase (PKAs), 345, 347
- AMPA receptor(s), 349  
GluR2/3, 350  
and NMDA receptors  
(NMDARs), 336, 342,  
344, 345, 347  
and the synapse, 335–36
- AMPAkines, 270
- Amphetamine(s)  
and *C. elegans*, 525  
and dopamine transporter  
(DAT)-KO mice, 270,  
271–72  
in mutant mice, 277  
in norepinephrine  
transporter (NET)-KO  
mice, 274  
in serotonin transporter  
(SERT)-KO mice, 273
- Amyl nitrite, 99
- Amyloid  $\beta$ -protein (A $\beta$ )  
A $\beta$ 40  
and Alzheimer's disease

- studies, 557, 560–61,  
563–64, 571, 572  
immunization, 568
- A $\beta$ 42  
and Alzheimer's disease  
studies, 557, 560–61,  
562, 563–64, 571, 572  
immunization, 564–68,  
570, 573  
monoclonal antibodies  
directed against,  
568–69
- A $\beta$  plaques  
monoclonal antibodies  
directed against,  
569–70
- in Alzheimer's disease  
brains, 546–47  
and amyloid  $\beta$  protein  
precursor (APP), 548–49  
and cholesterol, 572–73  
clearing it from the brain,  
564–71  
and familial Alzheimer's  
disease, 549, 550  
immunotherapy, 575  
neurotoxicity, 574  
production of, 557, 565  
and  $\beta$ -secretase, 555  
and  $\gamma$ -secretase, 557, 558  
and  $\alpha$ -secretase, 571  
and  $\gamma$ -secretase inhibitors,  
561–64  
in transgenic mouse  
models, 550
- Amyloid  $\beta$ -protein precursor  
(APP), 558  
and  $\beta$ -secretase, 554, 572  
and  $\gamma$ -secretase, 556  
and  $\alpha$ -secretase, 571–72  
and  $\gamma$ -secretase inhibitors,  
561  
biology of, 548–49  
and the pathogenesis of  
Alzheimer's disease, 549  
processing, 548–49  
Swedish mutant, 555
- in transgenic mouse  
models, 550
- Amyloid hypothesis  
for Alzheimer's disease,  
573–74, 575–76
- AN-1792  
and Alzheimer's disease  
studies, 570–71
- Aneurysm  
brain, 598–99
- ANGII, 106
- ANGII type 1 (AT-1), 107
- Angina  
and aspirin, 465  
and L-arginine, 110
- Angina pectoris  
and chelation therapy, 471  
treatment of, 99–100,  
105–6
- Angioplasty  
coronary, 100  
restenosis after, 585,  
590–93
- Angiotensin  
renin-angiotensin-  
aldosterone pathway,  
107
- Angiotensin II (ANGII), 100
- Angiotensin converting  
enzyme (ACE)  
inhibitors, 106–7  
and nitrate tolerance, 101
- Anion transporters, 641–42
- Anterior deirids (ADEs)  
and *C. elegans*, 523
- Anthracycline, 206
- Anti-A $\beta$  monoclonal  
antibodies (mAb), 564
- Antianginal agents, 444
- Antiarrhythmic agents, 444
- Antiarrhythmic drugs, 445
- Antibiotics  
and QT prolongation  
potential, 444  
reduced the number of  
deaths, 464
- Antibodies, 609
- and adeno-associated viral  
(AAV) vectors, 417  
and diazeniumdiolates, 604
- Anticancer agents  
and P-glycoprotein, 286
- Anticoagulants  
risks with, 593
- Anticonvulsants, 551
- Antidepressants, 444  
and attention-deficit  
hyperactivity disorder  
(ADHD), 271  
and dopamine transporter  
(DAT), 528  
in norepinephrine  
transporter (NET)-KO  
mice, 274, 275
- Antifungal agents, 444
- Antihistamines, 444, 447
- Antihistaminics, 640
- Antimalarials, 444
- Antioxidant(s)  
and atherogenesis, 110  
and calcium channel  
blockers (CCBs), 106
- Antioxidant response element  
(ARE), 233–53  
and cell signaling  
pathways, 246–52, 253  
transcription factors acting  
on, 240–46, 251
- Antipsychotic agents  
and Alzheimer's disease,  
551
- Antipsychotics, 444
- Antipyrine, 13, 20, 21  
and cigarette smoking, 18  
oxidative metabolism of,  
18, 19
- Antiretroviral  
resistance  
and St. John's wort,  
479
- Antiretroviral treatment,  
297–98
- Antisense chimeras  
and cancers, 367

- Antisense DNA oligomer, 367
- Antisense oligonucleotides, 80  
and telomerase, 363, 366
- Aph-1  
and  $\gamma$ -secretase, 559, 560
- Apolipoprotein (apo) A-I, 646-47
- Apolipoprotein (apo) E  
and Alzheimer's disease, 549-50
- ApoE4  
and A $\beta$ , 572  
and Alzheimer's disease, 549-50  
and the blood-brain barrier, 633
- Apoptosis, 104  
and cancer treatments, 202, 203, 207, 208, 213, 214, 217  
cell death by, 362  
and the dose-effect curve, 491  
germ cell, 126, 134, 136, 138, 139  
and Parkinson's disease, 532-33  
and telomeres, 361
- Apoptosis inducing factor (AIF), 534
- Apoptosis specific protein (ASP), 533
- Arachidonic acid, 84, 319-20
- Arg16, 386, 388, 394  
and asthma studies, 393
- Arg64, 396-97  
and  $\alpha_2$  adrenergic receptors (ARs), 402
- Arg296  
residue of  $\beta$ -secretase, 554, 555
- Arg389, 383, 385-86, 387, 390
- Arg492, 398, 399
- Aromatic amino acid  
decarboxylase (AAAD)  
and *C. elegans*, 525
- Aromatic hydrocarbons  
metabolic activation of, 154
- Arrhythmias  
cardiac, 454  
lethal, 112, 443, 453  
risk of, 449  
triggers, 443
- Arrhythmogenesis  
mechanisms of, 449
- Arsenic  
and hormesis, 184
- Arterial thrombotic disorders  
and nitric oxide (NO), 98
- Arthritis  
and oxidative stress, 253
- Aryl-hydrocarbon receptor (AhR), 234, 235, 238, 250, 309-24  
ligands, 309-24  
signal transduction, 309-11
- Aryl-hydrocarbon  
receptor-nuclear  
translocator protein (ARNT), 234, 235
- Ascorbate  
and nitrate tolerance, 101
- Ascorbic acid  
and LDL oxidation, 110  
and S-nitrosothiols, 101  
synthesis, 5, 6
- Asimadoline  
and P-glycoprotein, 639
- ASK1, 253
- Asn251, 399
- Asp93, 555
- Asp379  
of  $\beta$ -secretase, 554, 555
- Aspartate, 558
- Aspartic protease(s), 552, 553, 555  
aspartic protease 2 (Asp2), 553  
inhibitors of, 555
- Aspartyl proteases  
and Alzheimer's disease, 552  
and presenilins, 558
- Aspirin(s)  
compared to nitroaspirin, 104  
development of, 464-65  
and gastrointestinal toxicity, 102  
nitric oxide (NO)-releasing, 103-4
- Astemizole (Hismanol), 443, 444
- Asthma, 151, 382  
and adrenergic receptor polymorphisms (ARPs), 392-95  
and S-nitrosothiols, 102
- AT-1 antagonists  
and angiotensin converting enzyme (ACE) inhibitors, 107
- Atenolol, 107-8
- ATF4 protein, 246
- Atherogenesis, 108  
oxidation hypothesis of, 110  
and oxidative modification of LDL, 109
- Atherosclerosis, 110  
and Alzheimer's disease, 572  
and antioxidants, 111  
and nitric oxide (NO), 98
- Atherothrombotic disease, 109
- ATP  
See Adenosine triphosphate
- Atria  
and cardiac electrical excitation, 441-42
- Attention-deficit  
hyperactivity disorder (ADHD), 261, 535  
and dopamine, 270, 522  
and dopamine transporter

- (DAT)-KO mice, 271-72
- Avidin**  
and binding affinities, 37  
and biotin, 39
- Azimilide**, 452
- Azo dye N-demethylase**  
induction of, 3-4
- Azo-link reductase**, 3-4
- Azothioprine**, 74
- B**
- "Baby boomer" generation, 464
- BACE1**, 553
- Bacteria**  
and endotoxin, 610  
and lipopolysaccharide (LPS), sensing, 611
- Bacterial infection**, 73
- Barbital**  
and CYP3A5, 164  
and liver microsomal enzymes, 6
- Basic region-leucine zipper (bZIP)**, 240-41, 245, 246, 247
- Bayer Company**, 465
- Beef**  
charcoal-broiled, 18
- Behavioral symptoms**  
in Alzheimer's disease, 551-52
- Benadryl®**, 6, 7
- Benz[a]anthracene**  
and human colon cell lines, 164
- Benzamidine**  
modifies into  
parafluorobenzamidine, 35
- Benzanthracene**  
and human colon cell lines, 164
- Benzimidazoles**, 321-22
- Benzo(a)pyrene (BaP)-DNA adduct**, 155
- Benzo[a]pyrene (BP)**, 5  
and cytochrome P450, 11-12  
enzyme induction by, 6-8  
hydroxylation of, 13-14  
and liver microsomal enzymes, 6
- Benzo[a]pyrene hydroxylase**  
and cigarette smoking, 17
- Benzodiazepine L7**, 452
- Benzodiazepines**, 551
- 7,8-Benzoflavone**, 13-14  
and xenobiotic metabolism, 20
- Benzoquinoid ansamycins**, 205
- Benzphetamine**  
and cytochrome P450, 11-12
- Beta (β) blockers**, 107-8, 453
- Beta-amyloid<sub>1-42</sub>**  
and blood-brain barrier functionality, 632  
and P-glycoprotein, 637
- Beta-carotene**  
and the Physicians' Health Study-II, 111
- Bifunctional inducers**  
explained, 235, 237, 238
- Bilirubin (BR)**, 184, 318
- Biliverdin (BV)**, 318
- Binding affinities**  
and relaxed complex methods, 40-41
- Binding affinity**  
and free energy calculations, 32-38  
and semi-empirical linear response theory, 39
- Biological thresholds**  
belief in universality of, 177
- Biologics Control Act**  
of 1902, 466, 467
- Biomarkers**, 219
- Biomedical devices**  
nitric oxide (NO)-releasing, 596
- Biosensor accuracy**, 597
- Bioterrorism**, 464
- Biotin**  
and avidin, 39
- Birfenidone**, 79
- Bladder tumor incidence**  
and 2-AAF, 499, 500  
and 4-ABP, 499
- Bleomycin (BL)**  
and lung injury, 75-77, 84
- Blood-brain barrier (BBB)**, 629-48  
as an organ, 630, 631-32  
and homeostasis and disease, 632-33  
methods to study transport, 633  
transport processes at, 629, 631, 634-40
- Blood pressure**, 442  
and Arg389, 387  
and NCX-4016, 104  
and PROLI/NO, 598  
and sildenafil, 112  
and single nucleotide polymorphisms, 99
- Blood-testis barrier**, 128-29
- Blood vessels**  
and diazeniumdiolates, 593-94, 595
- BMS-214662**, 216-17
- Body fat distribution**, 400
- Borage**  
and lung disease, 85
- Born model**  
and molecular dynamics simulations, 38
- Botanical product(s)**  
approval process, 471  
bioavailability and bioequivalence of, 471  
and financial incentives, 472  
research on, 475-81  
standardized, 476, 478
- Bovine serum albumin (BSA)**, 105
- Bradykinin**, 106, 107

- Brain  
 of the Alzheimer's disease patient, 546  
 aneurysm, 598-99  
 drug transport to, 629-30, 631  
 tumors  
   and P-glycoprotein, 638  
 See also Blood-brain barrier; Cerebral vasospasm; Cerebrovascular disease
- Breast cancer  
 and CCI-779, 212  
 chemotherapy, 206  
 and HER2, 205  
 and miltefosine, 213  
 and R115777, 218  
 See also Cancer(s), mammary
- Brefeldin A  
 and seminiferous tubule fluid, 134
- Broccoli, 19
- Brodie, Dr. Bernard, 5
- Bronchoalveolar lavage fluid (BALF), 77, 78, 79, 80, 84, 85
- Brownian dynamics simulations, 38
- Brussels sprouts, 19
- Bryostatins  
 and cancer treatments, 210-11
- Bupropione, 274
- Bureau of Chemistry, 466
- Burns, Dr. John, 5-6
- Butachlamol, 525
- 1,3-Butadiene  
 and carcinogenesis, 486
- Butylated hydroxyanisole (BHA), 236, 237, 241, 245
- C  
 C225, 199, 207  
 c-jun N-terminal kinase (JNK), 248, 249, 250, 253  
 c-Kit, 136-37  
 c-MYC  
   and telomerase, 363-64, 369  
 CAAX, 215, 217  
 Cabbage, 19  
 Cadherins  
   and NMDA receptors (NMDARs), 343  
 Cadmium (Cd)  
   at low doses, 191  
*Caenorhabditis elegans*, 521-34  
   apoptotic cell death pathway in, 533  
   dopamine signaling in, 523-26  
   and dopamine transporter (DAT), 526-28  
   and dopamine transporter (DAT)-1, 529, 530-31  
   as a model system, 522-23, 536  
   necrotic cell death in, 533  
 Caffeine, 472  
   and cigarette smoking, 18  
   metabolism of, 19, 21  
 Calcium (Ca), 335  
   Ca<sup>2+</sup>  
     and cardiac electrical excitation, 442  
     and PAF, 83  
   channel  
     blockers, 105-6  
     and dopamine, 528  
     modulators, 552  
 Calcium/calmodulin-dependent protein kinase II (CaMKII), 342, 343-45  
 Calcium calmodulin kinase  
   and mammalian dopamine transporters (DATs), 527  
 Calmodulin, 344  
 Calreticulin, 62
- Camptothecin, 209
- Cancer Research  
 page 450 of, 3
- Cancer(s)  
 and antisense chimeras, 367  
 and aspirin, 465  
 cells  
   and telomerase, 360, 363, 369  
 chemoprevention, 4, 5, 237  
 colon  
   and aspirin, 465  
   and MAPK, 212  
 and epidermal growth factor receptor (EGFR), 202  
 esophageal, 160  
   and aspirin, 465  
   and hormesis, 183  
 liver  
   aminoazo dye induced, 3-5, 22  
 mammary, 5  
 non-small cell lung cancer (NSCLC), 202, 203, 212, 214, 217, 218  
 ovarian cancer cells, 367  
 and the Physicians' Health Study-II, 111  
 risk assessment  
   governmental, 192  
   and hormesis, 188-89  
 risk due to  
   N,N-diethylnitrosamine (DEN), 497  
 skin  
   and ozone pollution, 192  
 stomach, 160-61  
 and telomerase inhibitors, 362, 367  
 and therapeutic agents, 253  
 therapy  
   and P-glycoprotein inhibitors, 638  
 treatments

- signal  
   transduction-directed,  
   199-220  
 and St. John's wort, 479  
 See also Breast cancer;  
   Carcinogenesis;  
   Carcinogenicity;  
   Carcinogen(s);  
   Carcinoma(s);  
   Hepatocarcinogenesis;  
   Hepatocarcinogens;  
   Leukemia(s);  
   Lymphoma(s);  
   Melanoma; Tumor(s)
- Caspase  
   and apoptosis, 533
- Carbachol, 108
- Carbamazepine (Tegretol),  
   551
- Carbohydrates  
   and diazeniumdiolates, 604  
   in the diet, 18  
   and reactive nitrogen oxide  
   species (RNOS), 98
- Carbon monoxide (CO), 8  
   and aminoazo dye  
   N-demethylase, 10  
   and hydroxylation of  
   testosterone, 10  
   and liver microsomes, 9
- Carboplatin, 202
- Carboxylesterase  
   and exposure to vinyl  
   acetate, 507  
   and the oral cavity, 512
- Carcinogenesis, 485-514  
   chemical, 2  
   and hormones, 183  
   in nasal olfactory  
   epithelium, 510  
   sequence of events, 487  
   See also Cancer(s);  
   Carcinogenicity;  
   Carcinogen(s)
- Carcinogenicity  
   of vinyl acetate in rats and  
   mice, 501-6
- See also Cancer(s);  
   Carcinogenesis;  
   Carcinogen(s)
- Carcinogen(s), 243  
   bladder, 2-3  
   chemical, 237  
   and cigarette smoking, 17  
   and CYPs, 150  
   and diazeniumdiolates, 604  
   environmental  
     human exposure to, 497  
   gastric, 161  
   and hormones, 184  
   low-dose linearity for, 177  
   metabolism, 2  
   and threshold mechanisms,  
   487-91  
   and thresholds, 485-514  
   tobacco-smoke, 159-60  
   See also Cancer(s);  
   Carcinogenesis;  
   Carcinogenicity
- Carcinoma(s)  
   endometrial, 367  
   heptocellular, 492  
   See also Cancer(s)
- Cardiac death  
   sudden, 449, 453  
   See also Coronary events;  
   Heart failure (HF)
- Cardiac function  
   and angiotensin converting  
   enzyme (ACE) inhibitors,  
   106-7  
   See also Heart
- Cardiac transplantation list,  
   395
- Cardiomyocytes  
   and carcinogenesis, 490
- Cardiomyopathy  
   and adrenergic receptor  
   polymorphisms (ARPs),  
   386, 387, 403-4
- Cardiovascular disease(s),  
   321  
   and deletion  
   polymorphism, 402
- and nitric oxide (NO), 98  
   and the Physicians' Health  
   Study-II, 111  
   and red wine, 192  
   See also Cardiovascular  
   disorders: Heart; Heart  
   failure (HF)
- Cardiovascular disorders  
   and nitric oxide  
   (NO)-releasing drugs, 113  
   and S-nitrosothiols, 101  
   See also Cardiovascular  
   disease(s): Heart; Heart  
   failure (HF)
- Cardiovascular medications  
   and Alzheimer's disease,  
   573
- Carrier-mediated transport  
   (CMT)  
   at the blood-brain barrier,  
   634
- Cartinoids, 320
- Caspase(s), 213  
   and *C. elegans*, 534
- Catechol-O-methyl  
   transferase (COMT),  
   263  
   and *C. elegans*, 525
- Catecholaminergic agents,  
   444
- Catecholamine(s)  
   and *C. elegans*, 524, 525  
   in norepinephrine  
   transporter (NET)-KO  
   mice, 275
- Catenins, 343
- Caveolae  
   function of, 635
- CCI-779, 211-12
- CD14  
   receptor for  
   lipopolysaccharide (LPS),  
   612, 613, 615, 621
- cdc25C phosphatase, 210
- CeDOP1  
   dopamine receptor, 525
- Cell(s)



- cycle arrest
  - and tumor incidence, 487, 490
- death
  - and Parkinson's disease, 532-34
  - and telomeres, 361, 362
- lines
  - human colon, 164
- natural killer (NK)
  - and gene therapy, 429, 430
- proliferation
  - and carcinogenesis, 490
  - and tumor incidence, 496
  - and vinyl acetate, 511, 512, 513
- senescence, 361, 362, 373
- signaling pathways
  - and the antioxidant response element (ARE), 246-52, 253
- T cells
  - and gene therapy, 429, 430
- and telomerase, 359
- types
  - in the G.I. tract, 159
  - within the lung, 151
  - more susceptible to toxicities, 152
- Cellular death, 528
- Cellular retinoic acid binding proteins (CRABPs), 58
- Central nervous system (CNS)
  - diseases, 633, 635
  - disorders
    - drug therapy for, 640
  - and HIV, 639
- Cephalic cells (CEPs)
  - and *C. elegans*, 523
- Cerebral vasospasm
  - and diazeniumdiolate therapy, 601
  - See also Brain;
- Cerebrovascular disease
  - Cerebrovascular disease and chelation therapy, 471
  - See also Brain; Cerebral vasospasm
- Cetuximab, 199, 207
- cGMP, 97
  - and renin, 106
- CGP57148B
  - and cancer treatment, 199, 200, 202, 219
- CHAOS trial, 111
- Chelation therapy
  - a study of, 471-72
- Chemical(s)
  - carcinogenesis, 2
  - environmental, 22
  - industrial, 151
  - scanning, 41
    - computational experiments, 38-39
- Chemoprevention
  - of cancer, 4, 5, 237
- Chemotherapy
  - hormetic responses in, 186
- Chloramphenicol acetyl transferase (CAT), 238, 239, 241, 242
- Chlorcyclizine
  - and cytochrome P450, 11-12
- Chloride channels
  - and P-glycoprotein, 637
- Chloroform
  - and CYP genes, 156
- 7-Chlorokynurenic acid, 644
- Chlorpromazine
  - and *C. elegans*, 525
- Chlorthion, 8
- Chlorzoxazone, 6, 7
  - oxidative metabolism of, 19
- Cholera
  - resurgence of, 464
- Cholesterol
  - and Alzheimer's disease, 572-73
  - and apolipoprotein (apo) A-I, 646-47
  - and P-glycoprotein, 637
- Choloroquine, 448
- Chromanol 293B, 452, 453
- Chromate
  - and nasal tumors, 151
- Chromatin
  - and retinoic acid receptors and retinoid X receptors, 47, 52, 53-54, 55, 60, 63, 64
- Chromosomal aberrations, 513-14
  - and acetic acid, 507
  - and vinyl acetate exposure, 508
- Chromosome(s)
  - end-to-end fusion, 361, 362, 369, 373
  - and telomerase, 359
  - and telomeres, 360, 361-62
- Cigarette(s)
  - and fetuses, 154
  - smoking, 22, 156
    - and CYP expression, 157
    - and drug metabolism, 17-18
    - and lung cancer, 151, 156
  - See also Smokers; Tobacco smoke
- Circadian rhythm, 317
- Circum-ventricular organs (CVOs), 631
- Cisapride (Propulsid), 444, 448
- Cisplatin, 202, 206, 207
- Clara cells, 151-52
- Claritin, 443, 444
- Clathrin, 634
- Cleaning agent, 126
- Clinical studies
  - informed consent to, 466

- Clinical trials  
and botanical products,  
474-75, 478  
and cancer treatments, 219
- Clofibrate, 8, 12
- Clotrimazole  
and CYP3A5, 164  
and drug metabolism, 16
- Clozapine, 270
- Coactivator-associated  
arginine  
methyl-transferase I  
(CARM1), 58-59
- Cocaine  
and dopamine transporter  
(DAT), 267, 268-69, 526,  
528, 531, 535  
and dopamine transporter  
(DAT)-KO mice, 268-69,  
270, 272  
in mutant mice, 277  
in norepinephrine  
transporter (NET)-KO  
mice, 274, 275  
in serotonin transporter  
(SERT)-KO mice, 273
- Codeine  
demethylation of, 8
- Cognitive decline  
and Alzheimer's disease,  
546
- Cognitive deficits  
and Alzheimer's disease,  
546
- Cognitive functions  
and blood-brain barrier  
functionality, 633
- Colchicine, 74  
and seminiferous tubule  
fluid, 134  
and spermatogenesis, 140
- Colitis  
ulcerative colitis (UC),  
299-300
- Collaen  
biosynthesis, 74, 75
- Collagen, 86  
accumulation of, 73, 74,  
77, 80, 81, 85  
synthesis, 84  
and TGF- $\beta$ , 77
- Colon  
cancer  
and aspirin, 465  
and MAPK, 212  
cell types in, 159  
cytochrome P450 in, 151,  
163-64
- Complementary and  
alternative medicine  
(CAM), 463-82
- Computational experiments  
chemical-scanning, 38-39
- Computer technology  
and drug design, 31-32, 41
- Congophilic amyloid  
angiopathy (CAA)  
and Alzheimer's disease,  
547, 549
- Contraceptives  
and St. John's wort, 479
- Copper (Cu)  
and S-nitrosothiols, 101
- Corn oil (CO)  
and lung disease, 85
- Coronary artery  
nitric oxide (NO) delivery  
to, 591-92  
See also Heart
- Coronary artery disease  
and balloon angioplasty,  
590  
and chelation therapy, 471,  
472  
See also Coronary  
atherosclerosis; Coronary  
heart disease (CHD);  
Heart; Heart failure (HF)
- Coronary atherosclerosis, 111  
See also Coronary artery  
disease; Heart
- Coronary events  
and deletion  
polymorphism, 402
- See also Cardiac death;  
Heart; Heart failure (HF)
- Coronary heart disease  
(CHD)  
and nitric oxide (NO), 98  
and sildenafil, 112  
and statins, 109  
therapy for, 99  
See also Coronary artery  
disease; Coronary  
atherosclerosis; Heart;  
Heart failure (HF)
- Coronary stenoses  
and L-arginine, 110
- Corticosteroids, 74
- Coumarin, 13, 236, 237, 238,  
241  
and CYP genes, 156  
and the esophagus, 160  
and grapefruit juice, 162
- Cranberry  
research, 476
- CREB binding protein (CBP)  
CBP/p300, 53, 54, 55, 58
- Crohn's disease (CD), 299
- Cryptogenic fibrosing  
alveolitis, 73  
See Idiopathic pulmonary  
fibrosis
- C3435T  
polymorphism of *MDR1*,  
293-94, 295, 296, 299
- Current Good Manufacturing  
Practice (CGMP), 466,  
468, 470
- Cyclin-dependent kinases  
(CKDs), 208, 209, 210
- Cycloheximide, 385
- Cyclooxygenase-2 (COX-2),  
85, 102
- Cyclophosphamide, 74, 206
- Cyclosporin  
and drug metabolism, 16  
and St. John's wort, 479
- Cyclosporine, 294, 296-97  
and grapefruit juice, 162
- CYPs

- in fetal tissues, 154  
in human nasal mucosa, 151, 152
- CYP1A  
and the G.I. tract, 160, 161, 162, 163, 164
- CYP1A1, 149, 234, 237, 238  
and the aryl-hydrocarbon receptor (AhR), 310, 313, 316, 318, 319, 320, 321, 323  
in the respiratory tract, 152, 154, 155, 156-57  
and tryptamine, 317
- CYP1A2, 149  
and the aryl-hydrocarbon receptor (AhR), 318  
and the G.I. tract, 160, 161, 163  
and the respiratory tract, 152, 155, 156, 157
- CYP2A, 157-58  
and the respiratory tract, 153
- CYP2A3, 158
- CYP2A5, 156
- Cyp2a5*, 158
- CYP2A6, 149  
and the G.I. tract, 160, 161  
and the respiratory tract, 152-53, 154, 155, 156, 157
- CYP2A7  
and the small intestine, 161
- CYP2A7, 153, 157
- CYP2A13, 149  
and the respiratory tract, 152-53, 154, 155, 156, 157
- CYP3A, 159, 160  
and the G.I. tract, 163, 164  
and the respiratory tract, 152, 154  
and St. John's wort, 479
- CYP3A3  
and the G.I. tract, 163
- CYP3A4, 149, 296, 297  
and the G.I. tract, 160, 161, 162, 163, 164  
and P-glycoprotein, 288  
and the respiratory tract, 152, 154, 157
- CYP3A5, 149  
and the G.I. tract, 160, 161, 162, 163, 164  
and the respiratory tract, 152, 156, 157
- CYP3A7  
and the G.I. tract, 161
- CYP4A  
and the G.I. tract, 160, 164  
and the respiratory tract, 152
- CYP1B1, 149  
and the G.I. tract, 161, 163, 164  
and the respiratory tract, 152, 154, 156, 157
- CYP2B  
and CYP induction, 157  
and the G.I. tract, 164
- CYP2B, 157-58
- CYP2B6, 149  
and the G.I. tract, 161  
and the respiratory tract, 152-53, 154, 157
- CYP2B7P, 153
- CYP4B1, 149  
and the G.I. tract, 160, 161  
and the respiratory tract, 152, 154, 157, 158
- CYP2C, 152, 157, 159  
and the G.I. tract, 161, 162, 164
- CYP2C8, 149
- CYP2C9, 149  
and the G.I. tract, 162
- CYP2C18, 149
- CYP2C19, 149  
and the G.I. tract, 162
- CYP2D6, 149  
and the G.I. tract, 159, 161
- CYP2E  
and the respiratory tract, 152
- CYP2E1, 149, 488  
and the G.I. tract, 160, 161, 164  
and the respiratory tract, 152, 154, 155, 156, 157
- CYP2F, 157-58
- CYP2F1, 149  
and the G.I. tract, 161  
and the respiratory tract, 152, 153, 154, 157, 158
- CYP4F12  
and the G.I. tract, 162
- CYP2G  
and the respiratory tract, 152
- CYP2G1, 156
- CYP2G1, 153
- Cyp2g1* gene, 158
- CYP2J  
and the respiratory tract, 152
- CYP2J1, 149  
and the respiratory tract, 152-53
- CYP2J2, 149  
and the G.I. tract, 160, 161, 162, 163  
and the respiratory tract, 152, 154
- CYP2S1  
and the G.I. tract, 161, 162  
and the respiratory tract, 153-154
- Cys492, 398
- Cysteine, 215, 235, 252, 253  
pro-drugs  
and lung fibrosis, 86, 87
- Cystic fibrosis  
transmembrane regulator protein (CFTR), 637
- Cytochrome P448, 11, 12
- Cytochrome P450 (CYP), 1, 3, 7, 8, 11, 14, 16, 100, 149-65, 603  
activation of, 16

- and the aryl-hydrocarbon receptor (AhR), 319
- in the colon, 151, 163-64
- and environmental factors, 22
- in the esophagus, 151, 159-60
- explained, 9
- in the gastrointestinal tract, 150, 151, 158-64
- and liver microsomes, 9-13
- and microsomal metabolism, 154-55
- in the respiratory tract, 150, 151-58, 164
- in the small intestine, 151, 161-63
- solubilization and purification of, 10-13, 22
- in the stomach, 151, 160-61
- Cytochrome P450 reductase (CPR), 159
- Cytokine IL-1, 614
- Cytokine release
  - and NCX-4016, 104
- Cytokines, 617
  - and ILF, 77-82, 83, 85, 87
- Cytoplasmic dyneins
  - and microtubules, 132-33, 134
- Cytotoxicity
  - and carcinogenesis, 490, 509, 510, 511
  - and HSV-1 vectors, 429
  - and nitric oxide (NO), 98
  - and tumor incidence, 496
  - and vinyl acetate, 512, 513
- Cytotoxin
  - and nitric oxide (NO), 98
- D**
- DAPT
  - secretase inhibitor, 561, 562
- DEA/NO, 588
- Decorin, 81
- Dementia
  - AIDS, 639
  - and Alzheimer's disease, 546, 551, 552, 573
  - and the blood-brain barrier, 632
- Deoxycholate
  - and aminoazo dye
  - N-demethylase, 10
- Deoxycorticosterone, 8
- Department of Agriculture, 466
- Dependoviruses, 414
- Depolarization
  - cardiac
    - and HERG channels, 445
  - and cardiac electrical excitation, 442
  - diastolic, 452
- Depression, 261
  - and Alzheimer's disease, 551
  - and St. John's wort, 481
- Desipramine
  - and dopamine transporter (DAT)-KO mice, 269
  - in norepinephrine transporter (NET)-KO mice, 274
- Deskar<sup>®</sup>, 79
- DETA/NO, 587, 588
  - in angioplasty treatment, 591-92
  - and cerebral vasospasm, 598-99
  - and pulmonary hypertension treatment, 600-1
- Detoxification
  - enzymes, 323
  - in the small intestine, 161
- Devalproex sodium (Depakote), 551
- Dexamethasone, 12
- Dextromethorphan, 21
- Diabetes
  - and polymorphisms, 396
- Diabetic men
  - and erectile dysfunction, 112
- Diacylglycerol, 213
- Diastole, 442
- Diazoniumdiolates, 585-605
  - diazoniumdiolated metal surfaces, 592-93
  - and erections, 601, 602
  - ionic, 586-89
  - structure, 586, 587
  - and toxicity, 603-4
- 2,6-Dichlorobenzonitrile
  - and CYP genes, 156
  - and CYP2A13, 153
- 5,7-Dichlorokynurenic acid, 644
- Diclofenac, 16, 105
- Diet
  - and aryl-hydrocarbon receptor (AhR) ligands, 313-15
  - and cancer risk, 238
  - effects on drug metabolism, 18-20
- Dietary Supplement Health and Education Act of 1995, 467-68
- Dietary supplements
  - legislation for the regulation of, 467
  - requirements for, 468-72
  - and structure/function claims, 468
- Diethyl maleate, 235, 236
- Diethylenetriamine/NO, 104
- Digitalis, 466
- Digoxin, 286, 287, 288
  - and heart failure, 466
- Dihomo gamma linolenic acid (DGLA), 85
- 8,9-Dihydro-8-(N<sup>7</sup> guanyl)-9-hydroxyafatoxin B1 (AFB1-N7-Gua) adduct, 491-92, 493
- 7,8-Dihydrodiol, 13

- 1,4-Dihydropyridine  
calcium channel blockers  
(CCBs), 105
- Dihydroxyphenylacetic acid  
(DOPAC)  
and *C. elegans*, 524, 525
- $\gamma$ -Diketone  
neurotoxicity, 129
- Diltiazem  
and tacrolimus, 639
- Dimethyl sulfate  
and BL-induced lung  
fibrosis, 76
- 7,12-Dimethylbenz[a]anthracene,  
5
- Dioxin, 8, 12  
and the aryl-hydrocarbon  
receptor (AhR), 309, 310,  
311, 313, 316, 317-18,  
319-20, 321  
and hormesis, 184  
at low doses, 191
- Dioxin responsive element  
(DRE), 310, 318
- Diphenhydramine, 6, 7
- Disease(s), 386  
and  $\beta_2$  adrenergic receptor  
(AR), 392  
and adrenergic receptor  
polymorphisms (ARPs),  
386, 404  
and the blood-brain barrier,  
632-33  
chronic, 464  
incidence  
decreased, 177  
and mutation, 382  
and nitric oxide (NO), 98  
orphan, 472  
and oxidative stress, 253  
susceptibility, 298-300
- 1,2-Dithiole-3-thione  
and the antioxidant  
response element (ARE),  
235, 237, 238
- Diuretics, 444
- hypokalemia due to, 449
- DMAEP/NO, 588  
and pulmonary  
hypertension treatment,  
600-1
- DNA  
adduct(s)  
and carcinogenesis, 495,  
496, 497, 498, 499  
and adeno-associated viral  
(AAV) vectors, 414-15,  
416-17  
and adenoviral vectors,  
424, 426  
damage, 362, 487, 488,  
490, 491  
and aflatoxin B1, 491  
and urban pollution,  
151  
end replication problem,  
361  
and exposure to vinyl  
acetate, 507-8  
and gene therapy, 413  
and HSV-1, 427, 428, 429  
and oncoretroviruses, 423  
repair, 487, 488-89, 490  
and styrene oxide, 488  
and telomeres, 361  
telomeric, 359, 360, 361,  
362, 367, 368, 371
- DNA binding domain (DBD)  
and nuclear receptors,  
49-50
- Docetaxel, 202, 207
- Dodson, John, 185
- Dofetilide (Tikosyn), 444,  
445, 446, 447, 448
- Donepezil (Aricept)  
and Alzheimer's disease,  
551
- DOPA decarboxylase, 277
- DOPAC, 528
- Dopamine (DA)  
in *C. elegans*, 523-26  
dopamine transporter(s)  
(DAT), 261-62  
and *C. elegans*, 523-26,  
529, 530-31  
dopamine transporter  
knockout (DAT-KO)  
mice, 262-72, 273,  
275, 276-77, 278,  
526-27  
dopamine transporters  
(DAT)-1, 529, 530-32  
mammalian and  
*C. elegans*, 526-28  
and Parkinson's disease,  
528-30, 535  
and Parkinson's disease  
(PD), 521, 522, 527,  
528-30, 535
- Dose-effect  
curve  
and carcinogenesis, 485,  
487, 488, 490, 491,  
494, 495  
relationships, 499
- Dose response(s)  
biphasic, 185  
dose-response curve(s)  
and genotoxic  
carcinogens, 499  
of vinyl acetate, 501
- dose-response  
relationship(s)  
biphasic, 186  
and genotoxic  
chemicals, 513  
and the hormetic  
paradigm, 189-91  
for  
N,N-diethylnitrosamine  
(DEN), 497  
U-shaped, 180, 181  
and the Yerkes-Dodson  
Law, 185
- hormetic, 179, 193  
hormetic biphasic, 182,  
183  
models, 184  
paradigms, 176  
revolution, 176-77, 193

- and risk assessment,  
188-89
- Doxorubicin, 202, 206, 207,  
211
- Droperido, 525
- Drosophila*, 614, 622
- Drosophila melanogaster*,  
613
- Drug(s)
- abuse, 261
  - addiction
    - and dopamine, 522
  - and the blood-brain barrier,  
629-48
  - and cardiac K<sup>+</sup> channels,  
443
  - over the counter (OTC),  
472
    - requirements for,  
468-70, 478
    - standards, 468
  - and CYPs, 150
  - delivery
    - and the nose, 152
  - design
    - computer-aided, 31-41
  - drug-drug interactions and  
P-glycoprotein, 288
  - drug-metabolizing  
enzymes, 1-22
  - effects on drug  
metabolism, 16-20
  - enzyme induction by, 5-6
  - and financial incentives,  
472
  - glutamatergic
    - and dopaminergic  
hyperactivity, 270
  - hydroxylation of, 12
  - and ILF, 73
  - interactions with  
complementary and  
alternative medicine  
(CAM), 478-80
  - legislation for the  
regulation of, 467
  - neuroprotective, 536
  - nitric-oxide releasing,  
97-114
  - number one, 465
  - orphan, 466-67
  - oxidative metabolism of,  
9-10
  - and P-glycoprotein,  
637-40
  - with QT-prolonging  
potential, 444
  - regulation in the U.S.,  
466-72
  - requirements for, 468-72,  
478
  - stages in development of,  
474-75
  - that block HERG, 447
  - that interfere with  
monoamine transporters,  
278
  - that modify behavioral  
symptoms in Alzheimer's  
disease, 551-52
  - transported by  
P-glycoprotein, 286,  
287-88, 296-97
- Drug metabolism, 630
- activation of, 14-16
  - and cigarette smoking,  
17-18
  - CYP-mediated, 150
  - effects of diet on, 18-20
  - effects of drugs on, 16-20
  - induction and inhibition of,  
16-20
  - intraindividual variability  
in, 20-22
- Drug Price Competition and  
Patent Term Restoration  
Act (Waxman-Hatch  
Act)
- of 1984, 467
- Durham-Humphrey  
Amendments
- of 1951, 466, 467
- Dust(s)
- inhalation of, 73
- wood
- and nasal tumors, 151
- Dynammin, 634
- Dyslipoproteinemia  
and polymorphisms, 396
- Dystonia  
and *C. elegans*, 525
- E**
- E-4031, 445, 446
- Echinacea, 476
- research on, 476, 477
- Edelfosine, 212-13
- Edema
- and nitric oxide (NO),  
98
- Edetate (EDTA) chelation  
therapy, 471-72
- EGFR-TK, 203
- Eicosanoids, 84-85
- Electrical excitation  
cardiac, 441-42
- Electrocardiogram (ECG),  
442
- Electrocardiographic  
abnormalities, 441, 442,  
449, 454
- Electrophile response element  
(EpRE), 238
- Embryogenesis, 48
- Enalapril, 107
- Encephalitis
- and the blood-brain barrier,  
632
- Endocytosis, 634-35
- Endoplasmic reticulum (ER)
- endoplasmic  
reticulum/Golgi, 348
  - and NMDA receptors  
(NMDARs), 338-39
- Endosomes
- and NMDA receptors  
(NMDARs), 341
- Endothelial dysfunction  
and nitric oxide (NO), 98
- Endothelial function  
and angiotensin converting

- enzyme (ACE) inhibitors, 106-7
- and L-arginine, 110
- and statins, 109
- and vitamin E, 111-12
- Endothelial nitric oxide synthases (eNOS), 100, 101
- and angiotensin converting enzyme (ACE) inhibitors, 107
- and calcium channel blockers (CCBs), 106
- and oxidized low-density lipoprotein, 109
- and statins, 108, 109
- Endothelial vasomotor function, 111
- Endothelin-1, 106, 107
- Endotoxin(s)
  - hematopoietic cells, 612
  - receptor
    - signal transduction from, 616-17
  - the term, 610
  - tolerance, 617
  - and Toll-like receptors, 609-22
- Environment
  - and drug metabolism, 20, 21-22
- Environment regulatory agencies
  - and hormesis, 188
- Environmental agents
  - and Parkinson's disease, 535
- Environmental clean up standards, 192
- Environmental contaminants, 309
- Environmental health dogmas, 191
- Environmental issues
  - and public media, 192
- Environmental Protection Agency (EPA)
  - cancer risk assessment, 188
  - and kidney tumors, 177
- Environmental toxicity
  - and the respiratory tract, 151
- Enzyme(s)
  - and  $\beta$ -secretase, 552
  - azo dye-metabolizing, 3-5
  - beta-site APP-cleaving enzyme (BACE), 553
  - and *C. elegans*, 525
  - cytochrome P450, 149-65
  - detoxification, 323
  - detoxifying, 488
  - DNA repair, 489, 490
  - drug-metabolizing, 1-22, 233-53
  - induction
    - by benzo[a]pyrene, 6-8
    - by drugs, 5-6
    - and polycyclic aromatic hydrocarbons, 3-5
    - by xenobiotics, 234, 235-38
  - and organic nitrate esters, 100
  - telomerase, 359-74
  - xenobiotic metabolizing, 309, 310, 323
- Ephedrine alkaloids, 472
- Epidemiological studies
  - of vinyl acetate
    - carcinogenicity, 506-7
- Epidermal growth factor receptor (EGFR), 202, 203, 205, 207
- Epinephrine, 393, 394, 399, 401, 403, 444
- and adrenergic receptors (AR), 381
- Epirubicin, 206
- Epithelial lining fluid (ELF)
  - and pulmonary fibrosis, 85
- Epoxide
  - genotoxic, 488
- Epstein-Barr virus
  - and HSV-1 vectors, 429
- Equine infectious anemia virus, 423
- Erectile dysfunction
  - in Carl Djerassi's novel, 586
  - therapy, 112-13
  - treatment of, 603
  - See also Erection(s)
- Erection(s)
  - erection-inducing drugs, 601, 603
  - penile
    - and nitric oxide (NO), 98
  - See also Erectile dysfunction
- ERG1, 445
- ERK1, 212
- ERK2, 212, 248
- Erlotinib, 199, 203
- Erythromycin, 444, 447
  - and grapefruit juice, 163
- Esophageal cancer, 160
  - and aspirin, 465
- Esophagus
  - cytochrome P450 in, 151, 159-60
- Essinophilic granuloma, 73
- Estradiol, 8
  - and cigarette smoking, 17
  - hydroxylation of, 17
- Estrogen
  - and St. John's wort, 479
- Estrone, 8, 17
- Ethane dimethane sulphonate (EDS)
  - and testicular atrophy, 138-39
- Ethanol, 8, 12
  - and drug metabolism, 16, 19-20
- Ethinylestradiol
  - and grapefruit juice, 162
- Ethionine, 10
- Ethnic groups
  - MDR1* genetic variants in, 289-91, 293-94
- 7-Ethoxycoumarin, 13, 19



- Ethoxyquin, 236, 237, 241  
 Ethylnitrosourea, 490  
 Etoposide, 202  
 Evening primrose oil (EPO), 85  
 Excitatory post-synaptic currents (EPSCs), 345–46, 348  
 Exercise  
   and polymorphisms, 387, 396  
 Extracellular matrix (ECM)  
   proteins, 73, 75, 77, 78, 82, 85  
 Extracellular regulated kinase (ERK), 247, 248, 249, 250  
 Extracorporeal membrane oxygenation (ECMO)  
   circuits  
   and diazeniumdiolates, 594, 596  
 Eye diseases  
   and the Physicians' Health Study-II, 111
- F**
- Fabric printing workers  
   and polyneuropathy, 126  
 Farnesyl protein transferase (GTT), 215  
 Farnesyl transferase  
   inhibitors, 199, 215–18  
 Farnesylpyrophosphate (FPP), 215  
   and statins, 108–9  
 Fas system, 139  
   and Sertoli cells, 136  
 Fat  
   body fat distribution, 400  
   in the diet, 18  
   mass, 402  
 Fatty acid  
   polyunsaturated  
     and lung disease, 85, 87  
 Federal Drug Administration (FDA)  
   and drug and dietary supplement requirements, 468–70, 471  
   present day, 466  
 Federal Food, Drug, and Cosmetic Act  
   of 1938, 466, 467  
 Federal Trade Commission  
   and claims in advertising, 468  
 Feline immunodeficiency virus (FIV), 423  
 Felodipine, 19  
   and grapefruit juice, 162  
 Fenamate, 453  
 Fetal tissues  
   CYPs in, 154  
 Fever  
   agent responsible for, 610  
 Fexofenadine  
   and P-glycoprotein, 287, 296, 297  
 Fibroblast growth factor (FGF), 204  
 Fibroproliferative diseases, 77  
 Filovirus (Ebola Zaire), 422  
 Financial incentives  
   and botanical products, 472  
   in the development of drugs, 466–67, 472  
 Five-year survival, 387  
 Flavone, 13, 14–15  
 Flavonoid(s)  
   and the antioxidant response element (ARE), 237, 250  
   and aryl-hydrocarbon receptor (AhR) ligands, 313  
   inhibit CYP3A4, 162  
   and multiple monooxygenases, 13–14  
 Flaviopiridol, 199, 207–9  
 Flecainide, 448  
 Flesinoxan, 639  
 Flexin, 6, 7  
 Flk1/KDR, 204  
 Fluid phase-mediated transport (FMT)  
   and the blood-brain barrier, 631  
 5-Fluorouracil (5-FU), 209  
 Fluoxetine  
   and dopamine transporter (DAT)-KO mice, 270  
 Foamy viral (FV) vector(s)  
   and gene therapy, 418, 421–23  
   properties of, 431  
 Foamy virus, 414  
 Folate  
   and nitrate tolerance, 101  
 Foods  
   manufacturing requirements for, 468  
   safety of, 466  
 Forearm blood flow (FBF)  
   and beta ( $\beta$ )-blockers, 108  
 Formaldehyde-induced fluorescence (FIF)  
   and *C. elegans*, 524  
 6-Formylindolo(3,2b)-carbazole (FICZ)  
   and aryl-hydrocarbon receptor (AhR) ligands, 316, 317  
 Foxglove  
   extracts of, 465–66  
 Free energy calculations  
   and drug design, 31, 32–38, 41  
   and the  $\lambda$  dynamics method, 33–34  
   and locally enhanced sampling (LES) method, 33  
   and solvent models, 36–38  
   and Zwanzig's perturbation theory, 35–36  
 Free radical(s)  
   and Parkinson's disease, 529  
   scavengers

- neuroprotective strategy, 552
- Fruits
- and aryl-hydrocarbon receptor (AhR) ligands, 313
- and cancer risk, 238
- G**
- $\gamma$ -Aminobutyric acid (GABA)
- GABA<sub>B</sub> receptors
- and the endoplasmic reticulum, 339
- G-quadruplex(es)
- and c-MYC expression, 364
- and telomeres, 368, 371–72, 373
- G-tetrads, 368
- GABA
- See  $\gamma$ -Aminobutyric acid (GABA)
- Galantamine (Reminyl)
- and Alzheimer's disease, 551
- Gamma-linolenic acid (GLA), 85, 87
- Gastrointestinal stromal tumors (GIST), 202
- Gastrointestinal toxicity
- and nitric oxide (NO)-aspirin, 104
- and nonsteroidal anti-inflammatory drugs (NSAIDs), 102
- Gastrointestinal tract
- cytochromes P450 in, 150, 151, 158–64
- and vinyl acetate exposure, 511
- GBR 12909
- and dopamine transporter (DAT), 528
- Geldanamycin, 205
- Gemcitabine, 207, 209
- Gene(s)
- and Alzheimer's disease, 550
- and the antioxidant response element (ARE), 233–53
- CYP
- and the G.I. tract, 158–64
- and the respiratory tract, 152–58
- defects
- and cardiac arrhythmias, 453–54
- delivery systems
- and gene therapy, 413–14
- and drug metabolism, 20
- expression, 310–11
- aryl-hydrocarbon receptor (AhR)-dependent, 312, 313, 314, 315, 316, 317, 319, 320, 321, 322, 323
- hTERT, 363
- and nuclear receptors, 48, 61, 63
- and familial Alzheimer's disease, 545, 549–50
- gene-dose effect
- and dopamine transporter expression, 266
- ras
- and cancer treatments, 215
- therapy, 114, 413–32
- viral delivery systems explained, 413–14
- with viral vectors, 413–32
- transcription
- and retinoids, 47, 52, 53, 63
- tumor suppressor, 199
- See also HERG (human ether-a-go-go-related gene)
- Genetic screen
- forward, 531–32
- Geranylgeranylpyrophosphate (GGPP)
- and statins, 108–9
- Germ cell(s)
- alterations in, 134
- apoptosis, 126, 134, 136, 138, 139
- c-kit, 137
- depletion of, 134
- maturation, 133
- and Sertoli cells, 128–29, 135, 140, 141
- Ginkgo biloba, 479, 481
- Ginseng, 476
- GISSI-Prevenzione trial, 111
- $\beta$ Glc-PYRRO/NO, 589, 604
- GLEEVEC<sup>®</sup>
- and cancer treatment, 199, 200, 202, 219
- Glu
- deleted, 400–1
- Glu27, 388, 389
- and hypertension, 395
- and obesity, 396
- Glucocorticoid cortisol
- and P-glycoprotein, 636–37
- Glucocorticoid receptor (GR), 55, 56
- Glucocorticoid receptor interacting protein (GRIP1), 55
- Glucocorticoids, 86
- Glutamate
- in *C. elegans*, 523
- and NMDA receptors (NMDARs), 336
- receptors, 350
- Glutaraldehyde
- microtubules treated with, 133–34
- Glutathione (GSH), 85–86, 237, 245, 641
- Gly16, 388, 389, 393, 394

- and asthma studies, 393  
and hypertension, 395  
Gly49, 382, 383, 384–85,  
386, 387  
Gly389, 383, 385–86, 387,  
390, 404  
Gly648, 448  
Glyceryl trinitrate, 99  
Glycine, 336  
Glycoproteins  
and HSV-1 virus, 428  
and retroviruses, 422  
Gonadotropin releasing  
hormone (GnRH)  
and testicular atrophy, 138  
Government  
toxicological agenda, 176  
Governmental agencies  
and established paradigms,  
177  
Governmental cancer risk  
assessment, 192  
GR 127935, 274  
Grapefruit juice, 19, 162–63,  
165  
Green fluorescent protein  
(GFP)  
and dopamine transporter  
(DAT), 528, 529  
GTP cyclohydrolase  
(GTPCH)  
and *C. elegans*, 525  
Guanine  
and AFB1 epoxide, 491  
Guanine nucleotide binding  
proteins (G-proteins),  
381  
3',5'-Guanosine  
monophosphate  
(cGMP), 601  
Guanylate cyclase, 97  
and CYP3A4, 164
- H**  
Halogenated aromatic  
hydrocarbon (HAH),  
309, 311–12  
Haloperidol, 270, 525, 551  
and *C. elegans*, 525  
Hantavirus, 464  
Haplotypes, 387, 390–92,  
394, 404  
Hazard  
assessment, 192  
and hormesis, 184,  
186–87  
and regulatory agencies,  
176  
process of, 175  
Health  
of the American people,  
463  
and complementary and  
alternative medicine  
(CAM), 463  
effects  
beneficial and adverse,  
187  
Heart  
and  $\beta_2$  adrenergic receptor,  
390, 395  
attack  
and aspirin, 465  
disease  
and inhaled nitric oxide,  
114  
how it works, 441–42  
and  $I_{Kr}$ , 445–49  
rate, 390  
and Arg389, 387  
sudden increases in, 454  
transplant rejection  
and St. John's wort, 479  
See also Cardiac death;  
Cardiac function; Cardiac  
transplantation list;  
Cardiovascular disease(s);  
Cardiovascular disorders;  
Cardiovascular  
medications; Coronary  
artery; Coronary artery  
disease; Coronary  
atherosclerosis; Coronary  
events; Coronary heart  
disease (CHD); Heart  
failure (HF); Myocardial  
infarction (MI)  
Heart failure (HF)  
and  $\beta_1$  adrenergic receptor  
polymorphisms (ARPs),  
386–87  
and  $\beta_2$  adrenergic receptor  
polymorphisms (ARPs),  
395  
and adrenergic receptor  
polymorphisms (ARPs),  
403–4  
after myocardial infarction  
(MI), 107  
and digoxin, 466  
and nitric oxide (NO), 98  
and stroke volume, 100  
See also Cardiac death;  
Coronary events; Heart  
Heat shock protein 90, 205,  
310  
Helmholtz free energy  
and solvent models, 37–38  
and Zwanzig's perturbation  
theory, 32–33, 35  
Help virus  
and Ad vectors, 425  
Hematopoietic cells  
and endotoxin sensing, 612  
Heme complexes  
and the antioxidant  
response element (ARE),  
235  
Hemophilia B  
and gene therapy, 430  
Hepatic drug metabolism, 5  
Hepatocarcinogenesis  
aflatoxin B1-induced, 238  
See also  
Hepatocarcinogens; Liver  
Hepatocarcinogens, 603–4  
See also  
Hepatocarcinogenesis;  
Liver  
HER2  
and cancer, 205–6, 207

- Herbal medicines  
and safety and efficacy,  
480–81, 482  
See also Herbal products;  
Herbal remedies
- Herbal products, 315  
and drug interactions,  
475–76, 478–80  
See also Herbal medicines;  
Herbal remedies
- Herbal remedies, 22  
and prescription drugs, 16  
See also Herbal medicines;  
Herbal products
- Herbicides  
and hormetic effects, 186
- Herbimycin, 205
- Herceptin, 199, 205–7
- HERG (human  
ether-a-go-go-related  
gene), 443  
channels, 445  
and  $I_{Kr}$  current, 445–46  
 $I_{Kr}$ /HERG blockade,  
446–49  
 $K^+$  channels, 443, 445,  
446–49  
and methanesulfonanilides,  
448  
vestibule, 448–49
- Herpes simplex virus type 1  
(HSV-1)  
structure and replication,  
427–28  
vector(s)  
development and  
production, 428  
properties of, 431  
tropism and  
transduction, 428–29
- Herpes simplex virus type 1  
(HSV-1) vectors  
and gene therapy, 414,  
427–29
- Herpes virus  
and adeno-associated viral  
(AAV) vectors, 414–15
- Hexamethylphosphoramide  
(HMPA)  
and CYPs, 153, 155, 156  
2,5-Hexanedione (2,5-HD)  
exposure  
and germ cell death, 136  
microtubules treated with,  
133–34  
and testicular injury,  
125–41
- Hexobarbital, 7, 13
- High-throughput screen  
(HTS), 535–36
- Hippocrates, 464, 465
- Histamine  
and *C. elegans*, 524
- Histone acetyl transferase  
(HAT), 52, 53, 54, 55
- Histone acetylation  
and coactivators, 63
- Histone deacetylase(s)  
(HDAC), 52  
and corepressors, 63
- HIV  
See Human  
immunodeficiency virus  
(HIV)
- HMR 1275, 199, 207–9
- Holoenzyme  
telomerase, 359–74
- Homovanillic acid  
and *C. elegans*, 524
- HOPE trial, 111
- Hormesis, 175–93  
acceptance of, 176–77  
evidence of, 177–84  
impediments to acceptance  
of, 191–92  
legal implications of, 192  
in non-toxicological fields,  
185–86  
not seen too often, 177  
and risk assessment,  
186–92
- Hormetic hypothesis  
mechanism argument  
against, 182
- Hormone nuclear receptors,  
47–64
- Hsp90 protein, 363
- HSV-1  
See Herpes simplex virus  
type 1 (HSV-1)
- hTERT  
and telomerase, 359, 360,  
363, 365, 367, 369, 374
- hTR  
hTR RNA template, 359,  
363, 365, 367  
and telomerase, 359, 360,  
365
- humAb4D5, 206
- Human antimurine antibodies  
(HAMA), 206
- Human immunodeficiency  
virus (HIV)  
and inhibitor binding  
affinity, 39  
and *MDR1*  
polymorphisms, 297–98  
and P-glycoprotein at the  
blood-brain barrier, 639
- Human immunodeficiency  
virus type 1 (HIV-1)  
integrase, 40  
and lentiviruses, 419–21,  
423
- Human immunodeficiency  
virus type 2 (HIV-2), 423
- Huntington's disease, 534
- Hydralazine  
and nitrate tolerance, 101
- Hydrocarbons  
and BP hydroxylase, 5  
and enzyme induction, 22  
polycyclic  
and azo dye  
carcinogenesis, 3–5  
and charcoal-broiled  
beef, 18  
and enzyme induction, 6,  
7  
polycyclic aromatic  
hydrocarbons

- and enzyme induction, 3-5
  - and xenobiotic metabolism, 17-18
  - Hydrogen peroxide, 528, 529
  - 1-Hydroxy-2-amino-naphthalene, 2-3
  - 15-Hydroxyelcosatrienoic (15-HETrE) acid, 85
  - Hydroxyl radical
    - and Parkinson's disease, 528, 529
  - Hydroxylation, 6, 7
    - of benz[a]pyrene, 13-14
    - and liver microsomal fatty acid, 10-11
    - of testosterone, 8-10, 22
    - of zoxazolamine, 14-15
  - Hydroxymethylglutaryl (HMG)-CoA reductase inhibitors, 108-9
  - 5-Hydroxytryptophan (5-HTP)
    - and *C. elegans*, 525
    - and dopamine transporter (DAT)-KO mice, 270
  - Hyperactivity
    - and dopamine transporter (DAT)-KO mice, 269-70, 271, 272
    - in mice, 273
  - Hypercholesterolemia and L-arginine, 110
  - Hyperdopaminergia
    - in dopamine transporter (DAT)-KO mice, 269-71
  - Hyperforin
    - and drug metabolism, 16
  - Hypertension, 107, 382, 395
    - and adrenergic receptor polymorphisms (ARPs), 399, 400
    - and Arg389, 387
    - and the blood-brain barrier, 632
    - and deletion polymorphism, 402
    - and nebulolol, 108
    - and nitric oxide (NO), 98
    - pulmonary
      - and inhaled nitric oxide, 114
    - and sildenafil, 113
    - and single nucleotide polymorphism (SNP), 99
    - treatment of, 105
  - Hypertrophy
    - and adrenergic receptor polymorphisms (ARPs), 399
  - Hypochlorous acid (HOCl)
    - and BL-induced lung fibrosis, 76
  - Hypocholesterolemic agents, 444
  - Hypokalemia, 449
  - Hypotension
    - postural, 298
- I**
- Ibuprofen
    - and A $\beta$ 42, 563-64
  - Ibutilide (Covert), 444, 446
  - Idiopathic pulmonary fibrosis (IPF), 73-87
    - and pirfenidone, 79
  - I $K_r$ , 443, 445-49
    - blockade, 449
    - role in the heart, 445
  - I $K_s$ , 443, 445, 450-54
    - autonomic regulation of, 451-52
    - blockade, 452
  - IL-1, 83
  - IL-1 $\alpha$ , 79
  - IL-6, 83
  - Ile164
    - polymorphism, 388, 389, 390, 395
  - Imatinib mesylate
    - and cancer treatment, 199, 200, 202, 219
  - Imipramine
    - and dopamine transporter (DAT), 528
  - Immune system
    - responses to microbial poisons, 609-22
  - Immunity
    - two types of, 609
  - Immunotherapy
    - for Alzheimer's disease, 564-71, 573
  - Impotence
    - treatment of, 112
    - See also Erectile dysfunction
  - Incontinence
    - and adrenergic receptor polymorphisms (ARPs), 399
  - Indapamide, 452
  - Indigenous peoples, 464
  - Indigo, 317, 318
  - Indinavir, 297
    - and St. John's wort, 479
  - Indirubin, 317, 318
  - Indole acetic acid, 316, 317, 321
  - Indoles, 316-18
    - and human colon cell lines, 164
  - Indomethacin
    - and A $\beta$ 42, 563-64
  - Infection(s), 618, 620
    - and echinacea, 476
  - fungals
    - and flies, 614
    - gram-negative, 611, 618
    - immune responses to, 610
  - Infectious diseases
    - and S-nitrosothiols, 102
  - Inflammation, 74, 612
    - lung, 80
    - and lung fibrosis, 85
  - Inflammatory bowel disease
    - and *MDRI* polymorphisms, 299-300
  - Inflammatory cells, 77-83
  - Inocula, 618-20
  - Insulin secretion, 402

## Integrins

- and ILF, 82-83, 87
- and neurons, 346

Interferon gamma (INF- $\gamma$ ), 80-81

- Interleukin-6 (IL-6)
- and Bryo 1, 211
- and NCX-4016, 104

## Internet

- and complementary and alternative medicine (CAM), 464

## Ion channels

- cardiac, 441-42

## Ioratadine (Claritin), 443, 444

## Ipsapirone, 274

## IRAK gene

- and LPS, 616

## IRAK4 gene

- and LPS, 616, 621, 622

## Iressa

- and cancer treatment, 199, 202-3

## Irinotecan, 209

- and St. John's wort, 479

## Iron (Fe)

- and the brain, 644-45
- and dopamine, 528, 529

## Ischemia

- and nitrate, 100

## Isoniazid, 12

## Isoproterenol

- and adrenergic receptor polymorphisms (ARPs), 384, 385, 388
- and  $I_{Ks}$  blockers, 453

## Isosafrole, 8, 12

- and CYP3A5, 164

## Isosorbide 5-mononitrate, 99

## Isosorbide dinitrate, 99

## Isosorbide mononitrate, 112

## Isothiocyanate(s), 235, 236, 238, 248

- and human colon cell lines, 164

## J

## JNK1

- protein kinases, 250

## K

## Kaempferol

- inhibits CYP3A4, 162

## Kallikrein

- and angiotensin converting enzyme (ACE) inhibitors, 107

## KCNE1, 450, 451, 452, 453-54

## KCNQ1, 450, 451, 452, 453-54

## Kefauver-Harris Drug

- Amendments
- of 1962, 466, 467

## Kelch-like-ECH-associated protein 1 (Keap 1), 246, 247, 251, 252, 253

## 7-Ketocholesterol

- and the aryl-hydrocarbon receptor (AhR), 321

## Kidney tumors

- and the EPA, 177

## Kinase(s), 212

- kinase/phosphatase interactions, 343-45
- MAP, 342, 343
- protein

- and the antioxidant response element (ARE), 246-52

## rapamycin, 211

## serine/threonine kinase

- antagonists, 207-10

## and telomerase, 359-60

- tyrosine inhibitors, 200-7

## Kinesins

- and microtubules, 132-33, 134

## Kinins

- and angiotensin converting enzyme (ACE) inhibitors, 107

## Kola nut, 472

## KvLQT1, 450

## L

## L86-8275, 199, 207-9

## L-778,123, 215-16

## L-arginine, 108, 110

- and nitrate tolerance, 101
- and nitric oxide (NO), 97

## L-DOPA

- and *C. elegans*, 524
- and dopamine transporter (DAT)-KO mice, 264
- and Parkinson's disease, 521

## L-mevalonate

- and statins, 108

## L-NAME, 107

- and penile erections, 113

## L-NMMA, 110

## Lacidipine, 106

## Large intestine

- cell types in, 159

## Large neutral amino acid

- transporter
- and the blood-brain barrier, 643-44

## Latency associated transcripts (LAT)

- and HSV-1 infection, 428

## LDL

- See Low-density lipoprotein

## Lead (Pb)

- at low doses, 191

## Learning, 335, 336

## Learning environments, 185

## Left ventricular (LV)

- dysfunction, 107

## Legislation

- for the regulation of drugs
- and dietary supplements, 467

## Lenti vectors

- properties of, 431

## Lentiviral vectors

- and gene therapy, 419–21, 423, 430
- nonhuman, 423
- Lentivirus(es), 414
  - and gene therapy, 418, 419–21
- Leukemia(s)
  - and Bryo 1, 211
  - childhood acute lymphoblastic leukemia (ALL), 298
  - chronic myelogenous leukemia (CML), 200, 202, 219
  - and R115777, 218
  - and ras genes, 215
- Leukemic cells
  - and edelfosine, 213
- Leukotrienes, 84
- Life expectancy, 463–64
- Life style
  - and drug metabolism, 20, 21–22
- Ligand-binding domain (LBD)
  - and nuclear receptors, 50, 51, 55, 56
- Ligands
  - aryl-hydrocarbon receptor (AhR), 309–24
  - relaxed complex methods to discover, 40–41
- Light
  - chemical messengers of, 317
- Linear response theory
  - semi-empirical, 39, 41
- Lipid(s), 98
  - and the aryl-hydrocarbon receptor, 319–20
  - atherogenic, 109–10
  - lipid A
    - and TLR4 signaling, 621
- Lipolysis, 396, 398, 402
- Lipopolysaccharide (LPS), 610–22
  - sensing, 611
- sensitivity, 618–21
  - and survival, 621
  - set point responses, 618–21
  - signal transduction, 616–17
  - signaling complex, 612–13
  - tolerance, 618
- 5-Lipoxygenase, 85
- Liver
  - and Ad vectors gene therapy, 427
  - cancer
    - aminoazo dye induced, 3–5, 22
    - and CYP, 149–50
    - CYP2A6 in, 153
    - and dose-effect relationships, 499
    - microsomal enzymes, 8
    - microsomal monooxygenase, 6–7
    - microsomes
      - and cytochrome P450, 11, 14
      - cytochromes in, 9–13
      - and hydroxylation of testosterone, 9
    - monooxygenases in, 13–14
  - tumor(s)
    - and 4-ABP, 499
    - and aflatoxin B1, 491
    - induced, 488
    - and N,N-diethylnitrosamine (DEN), 494–97
- Liver-specific transporter-1 (LST), 641
- Locally enhanced sampling (LES) method
  - and free energy calculations, 33
- Locomotion
  - and dopamine, 526
  - and dopamine transporter (DAT)-KO mice, 271
  - in norepinephrine transporter (NET)-KO mice, 274
- Locomotor
  - progressive disorder, 534
- Long-term depression (LTD), 336
- Long-term potentiation (LTP) and NMDA receptors (NMDARs), 335, 336, 344, 345, 347, 349
- Long terminal repeats (LTR), 417, 418, 419
  - and FV vectors, 422
- Longevity
  - enhanced, 177
- Loperamide
  - and P-glycoprotein, 639
- Lovastatin, 572
  - and Alzheimer's disease, 573
- Low-density lipoprotein (LDL)
  - oxidation of, 110
  - oxidative modification of, 109
  - and statins, 109
- Low-dose linearity, 176
  - for carcinogens, 177
  - and hormesis, 192
- Low-dose risk assessment and hormesis, 191
- Low-dose stimulation, 186
- Low-dose stimulatory response
  - and the no observed adverse effect level (NOAEL), 183
- Lowest observed adverse effect level (LOAEL), 175
  - and hormesis, 176
- LTB4, 84, 85
- Lung
  - cancer
    - and cigarette smoking, 151
    - and NNK, 498
    - and polymorphisms, 155–56



- fibrosis, 73–87  
 bleomycin (BL) induced, 75–77, 78, 79, 80, 81, 82, 83, 84, 85, 86  
 interstitial, 73–87  
 injury  
 and bleomycin, 75–77, 84  
 non-small cell lung cancer (NSCLC), 202, 203, 212, 214, 217, 218  
 See also Respiratory tract  
 LY 294002, 250, 251  
 Lymphocytes, 609  
 Jurkat T, 364  
 Lymphoid  
 and the immune system, 610  
 Lymphoma(s), 210  
 mantle cell, 208, 209  
 and miltefosine, 213  
 See also Cancer(s)  
 Lys251, 399–400  
 Lysergic acid diethylamide (LSD)  
 and dopamine, 525  
 Lyssaviruses, 422
- M**
- Ma huang, 472  
 MAb225  
 murine monoclonal antibody, 207  
 Macrophages, 84  
 in chronically inflamed lung, 77  
 Lipopolysaccharide (LPS), 612, 613  
 Maf proteins  
 and the antioxidant response element (ARE), 240, 242, 243–45, 247, 253  
 Magnesium (Mg), 335  
 MAHMA/NO, 588  
 and extracorporeal membrane oxygenation (ECMO) therapy, 594, 596  
 Mammalian target of rapamycin (mTOR), 211  
 Mammals  
 and lipopolysaccharide (LPS), 610–11, 615, 618  
 and Toll-like receptors (TLRs), 614  
 Mammary cancer, 5  
 MAPK  
 See Mitogen activated protein kinase (MAPK)  
 Market exclusivity  
 and drugs, 472  
 Mating  
 and dopamine neurons, 526  
 McArdle Laboratory for Cancer Research, 2  
 McNeil Laboratories, 6  
 MD-2, 613, 615, 621  
 MDR  
 See Multidrug resistance  
*MDR1*  
 C3435T polymorphism of, 293–94, 295, 296, 299  
 gene  
 and P-glycoprotein, 286–89  
 and SNPs, 289, 292, 293–94, 297, 299, 300  
 and P-glycoprotein, 636  
 structural variability of, 289–92  
*MDR1* mRNA expression, 295  
*MDR1* polymorphisms, 285–301  
 and clinical outcome, 297–98  
 and disease susceptibility, 298–300  
 and P-glycoprotein expression, 294–95, 300–1  
 and P-glycoprotein function, 296–97, 300–1  
 Mechanosensation  
 and dopamine, 526  
 Medical devices  
 thrombogenicity of, 593–96  
 Medicine(s)  
 complementary and alternative medicine (CAM), 463–82  
 clinical trials of CAM therapies, 481  
 increase in use of, 464  
 out-of-pocket expenditures for, 464  
 product development, 474–75  
 products, 471  
 regulation in the U.S., 466–72  
 research on, 472–75  
 safety of, 466  
 Melanoma, 210  
 and Bryo 1, 211  
 cells, 367  
 Melanotransferrin (MTf), 645  
 Melatonin, 316–17  
 Melfinavir  
 and the *MDR1* genotype, 296  
 Melphalan, 643  
 Memantine  
 and Alzheimer's disease, 551  
 Membrane aspartic protease 2 (memapsin2), 553  
 Membrane-associated  
 guanylate kinases (MAGUKs)  
 and NMDA receptors (NMDARs), 337, 342, 348, 349  
 Memory, 335, 336, 348  
 and Alzheimer's disease, 546  
 Meningitis  
 and the blood-brain barrier, 632

- Meningococcal sepsis, 618
- Meperidine, 6, 7  
and cigarette smoking, 18
- Meprobamate, 20
- Mercury  
at low doses, 191
- Metabotropic glutamate  
receptors (mGluRs), 350
- Metachromatic  
leukodystrophy  
and gene therapy, 430
- Metal(s)  
heavy  
and the antioxidant  
response element  
(ARE), 235, 236  
heavy metal poisoning, 471  
metal ion chelators  
neuroprotective strategy,  
552  
nitric oxide (NO)-releasing  
metal surfaces, 592, 593
- Metaplasia  
intestinal, 160, 161
- Methamphetamine  
chronic abusers, 277  
and dopamine transporter  
(DAT)-KO mice, 268
- Methanesulfonanilides, 446,  
448
- Methionine, 215
- Methosymethyl (MOM), 587
- 2'-Methoxyacetophenone  
and CYP2A13, 153
- Methyl- $\beta$ -cyclodextrin, 572
- 3-Methyl-4-monomethylaminoazobenzene  
(3-Me-MAB), 6, 7, 8
- 1-Methyl-4-phenyl-1,2,3,  
6-tetrahydropyridine  
(MPTP), 268, 529, 533
- 1-Methyl-4-phenylpyridinium  
ion (MPP<sup>+</sup>), 268, 529,  
533
- Methyl *n*-butyl ketone, 126
- Methyl *n*-butyl methane  
converted to  
2,5-hexanedione  
(2,5-HD), 127
- 3-Methylcholanthrene, 3-5,  
7, 9, 10, 11, 12, 22  
and human colon cell lines,  
164
- (+)-3,4-Methylenedioxy-  
methamphetamine  
(MDMA), 273
- 06-Methylguanine-DNA-  
methyltransferase  
(MGMT), 489-90
- 4-(Methylnitrosamino)-1-  
butanone (NNK)  
and CYPs, 153, 154, 155
- Methylphenidate, 551  
and dopamine transporter  
(DAT), 267, 526  
and dopamine transporter  
(DAT)-KO mice, 268-69,  
270, 271-72
- Mibefradil, 16
- Mice  
and aflatoxin B1, 491  
CYP-knockout, 156  
dopamine transporter  
knockout (DAT-KO)  
mice, 262-72, 273, 275,  
276-77, 278  
lipopolysaccharide  
resistant, 611  
transporter mutant, 262-78  
See also Mouse
- Microsomal epoxide  
hydrolase (mEH)  
xenobiotic metabolizing,  
488, 489
- Microsomal metabolism  
and cytochromes P450,  
154
- Microsomes  
liver, 9-13
- Microtubule-associated  
proteins (MAPs), 130,  
132-33
- Microtubule(s)  
microtubule-dependent  
transport, 132-34, 135,  
139
- Sertoli cell(s), 128, 140-41  
and the tubulin hypothesis,  
129-32, 139
- Midazolam  
and grapefruit juice, 162
- Mild cognitive impairment  
(MCI), 546
- Miller, Drs. James and  
Elizabeth, 2
- Milrinone  
and penile erections, 113
- Miltefosine, 213
- Miltex<sup>®</sup>, 213
- Miniature excitatory  
post-synaptic currents  
(mEPSCs), 345-46
- minK-related protein 1  
(MiRP1), 445
- Minoxidil, 186
- Mitochondrial dysfunction  
and DA neuron  
degeneration, 528
- Mitogen activated protein  
kinase (MAPK), 200,  
201, 212, 382, 616  
and adrenergic receptor  
polymorphisms (ARPs),  
399, 403  
pathway  
lipopolysaccharide  
activated, 613  
and PD184352, 212  
signaling pathways, 246,  
247-50, 252, 253
- Mitomycin, 209
- MK-499  
and HERG, 446, 448-49
- Modafinil, 268
- Molecular dynamics  
simulation(s)  
and dynamic  
pharmacophore models,  
40  
of a protein, 31  
and relaxed complex

- methods, 40–41  
 and solvent models, 36–38  
 Molecular mechanics  
   molecular mechanics/  
   Poisson-Boltzmann-  
   surface area (MM/PBSA),  
   37–38  
 MOM-PIPERAZI/NO, 587,  
   589, 591  
 Monoamine oxidase (MAO),  
   263, 267  
   and *C. elegans*, 525  
   and dopamine, 528  
 Monoamine transporters,  
   261–78  
 Monoclonal antibodies  
   directed against A $\beta$ ,  
   568–70  
 Monofunctional inducers,  
   235, 237, 238, 248,  
   253  
   explained, 234  
 Monoxygenases  
   and cigarette smoking,  
   17–18  
   multiple, 8–10, 13–14  
   xenobiotic-metabolizing,  
   22  
 Mood disorders  
   and  $\alpha_2A$  adrenergic  
   receptor polymorphism  
   (ARP), 400  
 Morphine  
   demethylation of, 8  
   and dopamine transporter  
   (DAT)-KO mice, 271  
   in norepinephrine  
   transporter (NET)-KO  
   mice, 274  
   and P-glycoprotein,  
   637–38  
 Mouse  
   C3H/HeJ, 611, 613, 616  
   smart, 348  
   See also Mice  
 Moxisylyte, 113  
 MRP-efflux systems  
   and the blood-brain barrier,  
   641  
 Multi-unit search for  
   interacting conformers  
   (MUSIC), 40  
 Multidrug resistance (MDR),  
   286, 635, 638  
   multidrug resistance 2  
   (MDR2)  
     and P-glycoprotein, 636  
   non-P-glycoprotein  
   mediated, 641  
 Multiple sclerosis  
   and the blood-brain barrier,  
   632  
 Multivitamins  
   and the Physicians' Health  
   Study-II, 111  
 Murine leukemia virus  
   (MLV), 419  
 Murine monoclonal antibody,  
   205–6, 207  
 Mutation(s)  
   AFB1-N7-Gua adduct,  
   492  
   and *C. elegans*, 522–23,  
   530, 531, 532, 534  
   and disease, 382  
   genetic  
     and Alzheimer's disease,  
     549, 550  
   and hormesis, 183  
   presenilin missense, 557  
   Swedish double, 554  
   and TLR4, 617–18  
 MyD88, 614, 616, 621, 622  
 Myeloid  
   and the immune system,  
   609–10  
 Myeloperoxidase  
   and BL-induced lung  
   fibrosis, 76  
 Myocardial infarction (MI),  
   104  
   and aspirin, 465  
   heart failure (HF) after, 107  
   management of, 100
- N**
- N-acetyl-L-cysteine (NAC),  
   86  
 N-demethylase  
   aminoazo dye, 3–4, 6, 10  
   aminoazo dye  
     N-demethylase  
       and cigarette smoking, 17  
   N-demethylation, 6, 7  
   *n*-hexane, 125–26  
     converted to  
       2,5-hexanedione  
       (2,5-HD), 127  
   polyneuropathy, 126  
 N-methyl-aniline, 6, 7  
 N-methyl-D-aspartate  
   (NMDA)  
   and dopamine transporter  
   (DAT)-KO mice, 270  
 4-(N-methyl-N-  
   nitrosoamino)-1-  
   (3-pyridyl)-1-butanone  
   (NNK), 485, 488,  
   497–98, 513  
 N-nitrosodiethylamine  
   (NDEA)  
   and CYPs, 153, 155  
 N-nitrosomethyl-N-  
   amylamine  
   and CYPs, 160  
 N-nitrosomethylphenylamine  
   and CYP2A13, 153  
 N'-Nitrosomonocotine, 160  
 N-nitrosopyrrolidine  
   and PYRRO/NO, 603–4  
 NAD<sup>+</sup>  
   and BL-induced lung  
   fibrosis, 76–77, 87  
 NAD(P)H oxidase, 100  
 $\alpha$ -Naphthoflavone, 13  
 $\beta$ -Naphthylamine, 2–3  
 Naproxen sodium  
   and A $\beta$ 42, 563–64  
 Naringenin  
   inhibits CYP3A4, 162  
 Nasal mucosa  
   See Respiratory tract

- Nasal olfactory tissue
  - See Olfactory tissue(s)
- National Advisory Council
  - for Complementary and Alternative Medicine, 473
- National Center for
  - Complementary and Alternative Medicine (NCCAM), 463, 471
  - and complementary and alternative medicine research, 472-75
  - research on St. John's wort and other CAM therapies, 481
  - strategic plan, 473
  - studies of alternative medicine therapies interactions with drugs, 479-80
- National Heart, Lung, and Blood Institute, 471
- National Institutes of Health (NIH), 5, 6, 478
  - and complementary and alternative medicine (CAM) research, 472
  - study on St. John's wort, 479
- Native Americans, 464
- Natural product(s)
  - and medical practice, 464-65
  - regulation in the U.S., 466-72
- Nayeloid
  - and immunity, 622
- Nebivolol, 107-8
- Necrosis
  - and Parkinson's disease, 532-33
- Nervous system
  - and 2,5-hexanedione (2,5-HD), 126, 129, 139
  - C. elegans*, 523
- Neurobehavioral disorders
  - and dopamine neuronal dysfunction, 521-22
- Neurodegeneration, 521, 522, 527, 529, 530, 531, 532, 533, 534, 535, 536
- Neurodegenerative diseases
  - and scavenger receptors, 647
- Neurological diseases
  - and gene therapy, 430
  - resistance to xenobiotics, 157
- Neurological disorders
  - and dopamine, 522
- Neuronal death, 531
- Neuronal homeostasis
  - presynaptic, 262
- Neurons
  - cross-talk between, 346
  - and dopamine transporter (DAT)-KO mice, 265
- Neuroprotective strategies, 552
- Neurotoxicity
  - $\gamma$ -diketone, 129
  - and 2,5-hexanedione (2,5-HD), 126, 129
  - dopaminergic, 268
  - MPTP, 268
  - in mutant mice, 277
  - serotonergic, 268
- Neurotoxins
  - dopamine mimetic, 521
  - and dopamine transporter (DAT), 526
  - and monoamine transporters, 262
- Neurotransmission
  - C. elegans*, 523
  - dopamine, 522, 527, 530
- Neurotransmitters
  - and deficits of Alzheimer's disease, 547-48
  - and monoamines, 261-62, 277
- Neutrophils
  - and immunity, 622
  - and lung fibrosis, 75-76, 84
- New drug application (NDA), 472
- $\beta$ NF, 237, 238, 242, 248, 250, 251
- NF-E2 protein, 240, 241, 243, 244, 245, 246
- NF- $\kappa$ B, 214, 614, 615, 616, 617
- N(G)-monomethyl-L-arginine (LNMA), 108
- Niacin
  - and BL-induced lung fibrosis, 76-77
  - and ILF, 76-77, 78-79, 84
- Nicastrin
  - and A $\beta$ , 559
  - and  $\gamma$ -secretase, 559, 560
- Nicotine
  - and lung cancer, 156
- Nifedipine, 19, 106
- and grapefruit juice, 162
- Nisoxetine
  - and dopamine transporter (DAT), 528
  - and dopamine transporter (DAT)-KO mice, 269, 270
  - in norepinephrine transporter (NET)-KO mice, 275
- Nitrate(s)
  - ester
    - nitric oxide (NO)-releasing aspirins as, 103-4
    - organic, 99-101
    - tolerance, 100-1
- Nitrendipine, 106
- Nitric oxide (NO), 97-114, 106
  - and angioplasty, 591
  - and angiotensin converting enzyme (ACE) inhibitors, 107
  - and beta ( $\beta$ )-blockers, 107-8

- bioactivity of, 97–98  
 and cerebral vasospasm, 598  
 and CYP3A4 induction, 164  
 delivery systems, 105  
 and diazeniumdiolate(s), 585–605  
 and enzymes, 603  
 and erections, 601, 603  
 and ILF, 83–84  
 inhaled nitric oxide (INO), 114  
 and mucosal integrity, 102  
 nitric oxide  
   (NO)-nonsteroidal  
   anti-inflammatory drugs  
   (NSAIDs), 102  
 nitric oxide (NO)-releasing  
   metal surfaces, 592, 593  
 and pulmonary  
   hypertension treatment,  
   600–1  
 and statins, 108–9  
   therapeutic benefits, 604  
 Nitric oxide synthase(s)  
   (NOS), 84, 97, 110  
 Nitrite esters, 99–101  
 Nitroglycerin, 100, 111,  
   112  
 Nitrosamine(s)  
   and CYPs, 160  
   and nasal tumors, 151  
 Nitrovasodilators, 99–101  
 NMDA receptors  
   (NMDARs), 335–50  
   and endoplasmic reticulum  
   retention, 339–41  
   internalization of, 349–50  
   and kinase/phosphatase  
   interactions, 343–45  
 NR2 subunit  
   over-expressed, 348  
   and plasma membrane,  
   341, 345  
   processing in intracellular  
   compartments, 338–41  
   proteins that interact with,  
   337–38, 350  
   subunit assembly, 336–37  
   and the synapse, 335, 336,  
   340, 341, 342–50  
   synaptic and extrasynaptic,  
   345–46  
 N,N-diethylnitrosamine  
   (DEN), 485, 487, 490,  
   494–97  
 N,N-dimethylaniline  
   and CYP2A13, 153  
 NNK  
   See 4-(N-methyl-N-  
   nitrosoamino)-1  
   (3-pyridyl)-1-butanone  
 No observed adverse effect  
   level (NOAEL)  
   concept and derivation of,  
   186, 193  
   and hormesis, 175, 176,  
   177, 187  
   and the hormetic dose  
   response, 179  
   and low-dose stimulatory  
   response, 183  
 Nobel Prize  
   in Physiology or Medicine,  
   521  
 Nobiletin, 13  
 Nomifensine  
   and dopamine transporter  
   (DAT), 528  
 Non-protein sulfhydryl  
   (NPSH), 86  
 Non-small cell lung cancer  
   (NSCLC), 202, 203,  
   212, 214, 217, 218  
 Non-steroidal  
   anti-inflammatory drugs  
   (NSAIDs)  
   and A $\beta$ 42, 563–64  
 NONOates, 585–605  
 Nonsteroidal  
   anti-inflammatory drugs  
   (NSAIDs), 102  
   and APP  $\gamma$ -secretase  
   activity, 574–75  
 nitric oxide  
   (NO)-nonsteroidal  
   anti-inflammatory drugs  
   (NSAIDs), 102  
 Norepinephrine (NE), 403  
   and adrenergic receptors  
   (AR), 381  
   and amphetamine, 267  
   and attention-deficit  
   hyperactivity disorder  
   (ADHD), 271  
   and *C. elegans*, 524  
   and cocaine responses,  
   269  
   and heart failure, 386, 387  
   norepinephrine transporter  
   knockout (NET-KO)  
   mice, 273, 274–75,  
   276–78  
   norepinephrine transporter  
   (NET), 261–62, 268–69,  
   528  
   and psychostimulants, 278  
 Nortriptyline, 298  
   and cigarette smoking, 18  
 Nose  
   and drug delivery, 152  
   See also Olfactory tissue(s)  
 Notch  
   receptors, 557, 563  
   signaling, 563, 574  
 NR-binding  
   SET-domain-containing  
   protein 1 (NSD1), 57  
 Nrf1, 241, 242, 244, 245  
 Nrf3, 245, 246  
 Nrf2 protein  
   and the antioxidant  
   response element (ARE),  
   233, 240–43, 244, 245,  
   246, 247, 248, 249, 251,  
   253  
 Nuclear factor- $\kappa$ B, 78–79, 80,  
   84  
 Nuclear localization signals  
   (NLS)

and viral vectors, 423  
 Nuclear receptor corepressor  
 (N-CoR), 59–60, 62  
 Nucleoside transport systems  
 and the blood-brain barrier,  
 642–43  
 Nucleotide  
 nucleotide 17, 388  
 nucleotide 79, 388  
 nucleotide 145, 382  
 nucleotide 901, 400  
 nucleotide 964, 402  
 nucleotide 1165, 383  
 nucleotide 1441, 398

## O

Obesity  
 and  $\beta_2$  adrenergic receptor  
 (AR), 396  
 and  $\alpha_{2A}$  adrenergic  
 receptor polymorphism  
 (ARP), 400, 402  
 and Arg64  $\beta_3$  adrenergic  
 receptor polymorphism,  
 397–98  
 Octopamine  
 and *C. elegans*, 524  
 Office of Dietary  
 Supplements., 476  
 6-OHDA, 529, 530, 531, 532,  
 533, 534, 535  
 Oil  
 GLA-containing  
 and lung disease, 85  
 Olanzapine (Zyprexa), 551  
 Olfactory tissue(s), 512  
 exposure to vinyl acetate,  
 508–11  
 Oltipraz, 238  
 OM99-2  
 $\beta$ -secretase inhibitor,  
 555–56  
 Omeprazole  
 and drug metabolism, 16  
 Oncoretroviral vectors  
 and gene therapy, 419  
 properties of, 431

Oncoretroviruses  
 and gene therapy, 418, 419,  
 423  
 Oral cavity  
 and vinyl acetate in the  
 drinking water, 512  
 Oral contraceptives  
 and drug metabolism, 16  
 Organ system  
 and nitric oxide (NO),  
 589  
 Organic anion transporter  
 (OAT), 641–42  
 Organic anion transporter  
 polypeptide (oatp),  
 641  
 Orphan Drug Act  
 of 1983, 466, 467, 472  
 Orphenadrine  
 and liver microsomal  
 enzymes, 6  
 OSI-774, 199, 203  
 Ovarian cancer cells  
 apoptosis of, 367  
 Oxaliplatin, 202  
 Oxidative insult  
 and enzymes, 237  
 Oxidative stress, 233, 246,  
 250, 253  
 and 6-OHDA, 534  
 ARE-driven response to,  
 240  
 and cell death, 535  
 and dopamine neuron  
 degeneration, 528  
 Oxidized low-density  
 lipoprotein (oxLDL),  
 109–10  
 Oxygen (O)  
 consumption ( $VO_2$ )  
 and  $\beta_1$  adrenergic  
 receptor  
 polymorphisms  
 (ARPs), 387, 395  
 radicals, 98  
 Ozone pollution  
 and skin cancer, 192

## P

p23  
 protein, 363  
 p120, 58  
 p300  
 nuclear protein, 54  
 p300/CBP, 54, 55, 61  
 p300/Phospho-CREB  
 binding protein (CBP),  
 53, 54  
 P448  
 cytochrome P448, 11, 12  
 P450  
 See Cytochrome P450  
 (CYP)  
 P/CAF, 53, 54–55, 61, 63  
 P-glycoprotein (Pgp)  
 and the blood-brain barrier,  
 300, 635–40  
 and disease susceptibility,  
 298–99  
 and drug-drug interactions,  
 288–89  
 efflux pump  
 at the blood-brain  
 barrier, 635–36  
 and *MDR1* gene, 286–89  
 and *MDR1* polymorphisms,  
 291–92, 294–97, 300–1  
 physiological role of,  
 636–37  
 regulation of, 640  
 substrates, 286–88, 296–98  
 and HIV, 297–98  
 and xenobiotics, 285, 286,  
 298  
 P13 kinase pathway  
 LPS activated, 613  
 P13/MAPK, 203  
 P waves  
 on the ECG, 442  
 Paclitaxel, 202, 206, 207  
 Pain  
 and NMDA receptors  
 (NMDARs), 348  
 Panic  
 and  $\alpha_{2A}$  adrenergic

- receptor polymorphism (ARP), 400
- Paracetamol, 513-14
- Paraflex, 6, 7
- Parafluorobenzamidine  
benzamidine modified into, 35
- Parameters  
model  
comparing all, 34-35
- Paranoid psychosis  
and ECG T waves, 443
- Parkin gene, 535
- Parkinson, James, 521
- Parkinsonism  
resistance to xenobiotics, 157
- Parkinson's disease (PD), 261  
and cell death, 532-34  
and dopamine, 521, 522, 527, 528-30, 535  
and dopamine transporter (DAT), 528-30, 535  
and gene therapy, 430  
and *MRD1*  
polymorphisms, 300
- Paroxetine  
in norepinephrine transporter (NET)-KO mice, 274
- Patent protection  
and drugs, 472
- PD 98059, 248, 250, 251
- PDZ proteins  
and NMDA receptors (NMDARs), 335, 337, 340, 341, 342, 343, 348, 349
- Pelle, 621, 622
- Pen-2  
and  $\gamma$ -secretase, 559, 560
- Pentobarbital, 20  
and cytochrome P450, 11-12
- Peptide nucleic acids (PNAs)  
and telomerase inhibition, 365
- Peptides  
hormetic effects, 186  
and P-glycoprotein, 637
- Pericardium  
and angioplasty, 591, 592
- Perifosine, 213-14
- Peroxynitrite  
and ILF, 83-84  
and nitric oxide (NO), 98
- Perturbation theory  
Zwanzig's, 32, 35-36
- PGC-1, 57, 64
- PGE1, 85
- PGE2, 85
- pH  
and genetic toxicity, 507
- Phagocytic cells, 609
- Pharmaceutical industry  
and the regulatory environment, 466
- Pharmacist, 1, 2
- Pharmacokinetics  
and the blood-brain barrier, 629, 630
- Pharmacophore model(s)  
dynamic, 39-40  
for mining new drug leads, 41
- Phe656, 448
- Phenacetin  
and cigarette smoking, 17  
metabolism of, 21  
oxidative metabolism of, 18
- Phenobarbital, 7, 8, 9, 10, 11, 12, 22  
and drug metabolism, 16, 20  
and human colon cell lines, 164  
and liver microsomal enzymes, 6
- Phentolamine  
and penile erections, 113
- Phenylalanine, 643-44
- Phenylaminopyrimidines, 200
- Phenylbutazone, 21  
and liver microsomal enzymes, 6
- Phenylethyl isothiocyanate (PEITC), 244
- Phenytoin, 296, 638  
and cigarette smoking, 18  
and drug metabolism, 16
- Phospholipase C, 381
- Phosphatidylcholine, 11
- Phosphatidylinositol 3-kinase (PI3K), 250-51, 252, 253
- Phosphodiesterase (PDE), 601
- Phosphodiesterase type-5, 112-13
- Phospholipase C, 213
- Phosphorothioate (PS)  
PS-DNA oligomers, 365, 367
- Phosphorylation  
of adrenergic receptor polymorphisms (ARPs), 401, 402  
and dopamine transporter, 527
- PKA phosphorylation  
of  $I_{Ks}$ , 451, 452  
protein, 246, 247, 251-52, 253
- Tyr, 210
- Photooxidation  
Trp, 316, 317
- Physicians' Health Study-II (PHS II)  
and antioxidants, 111
- PICK1  
and dopamine transporter (DAT), 527, 531
- Pimozide, 525
- PIPERAZI/NO, 588
- Pirfenidone, 79-80
- P13K/Akt, 211
- PKA  
See Protein kinase A (PKA)
- Plant biology



- and hormesis, 185–86
- Plasma membrane
  - and NMDA receptors (NMDARs), 341, 345
  - and proteins, 338
- Platelet-activating factor (PAF), 83, 87
- Platelet-derived growth factor (PDGF), 80
  - platelet-derived growth factor (PDGFR)
    - and cancer treatments, 200, 203, 204
- Platelets
  - and nitric oxide (NO), 593–96
  - and nitric oxide (NO)-releasing aspirins, 103
- Poisons
  - immune responses to, 609–22
- Poisson-Boltzmann molecular mechanics/Poisson-Boltzmann-surface area (MM/PBSA), 37–38, 41
- Poisson-Boltzmann equation, 37
- Pollutants
  - and the hormetic hypothesis, 192
  - and nasal tumors, 151
- Pollution
  - and DNA damage, 151
- Poly (ADP-ribose) polymerase (PAP)
  - and BL-induced lung fibrosis, 76, 77
- Poly (vinyl chloride) (PVC)
  - and extracorporeal membrane oxygenation (ECMO) therapy, 594, 596
- Polyamine-modulated factor-1 protein (PMF-1), 246
- Polyamine response element (PRE), 246
- Polychlorinated biphenyls, 8, 12
- Polyethylenimine (PEI)
  - and diazeniumdiolated grafts, 594, 595
- Polyglutamine disorders, 534
- Polymorphism(s)
  - adrenergic receptor, 381–404
  - and *C. elegans*, 522
  - genetic, 165
  - and lung cancer, 155–56
  - MDRI*, 285–301
    - and clinical outcome, 297–98
    - and disease susceptibility, 298–300
  - restriction fragment length polymorphism (REL P), 398
- Polyneuropathy
  - and 2,5-hexanedione (2,5-HD) exposure, 129
  - n*-hexane, 126
- Polysaccharides
  - and diazeniumdiolateds, 604
- Posterior deirids (PDEs)
  - and *C. elegans*, 523–24
- Postsynaptic density (PSD), 337, 342, 343
- PSD-95
  - and NMDA receptors (NMDARs), 337, 342, 343, 344, 345, 347, 349, 350
- Postsynaptic dopamine receptors
  - and dopamine transporter (DAT)-KO mice, 265–66
- Potassium (K)
  - and cardiac electrical excitation, 442
  - K<sup>+</sup>
    - blockade, 441
  - K<sup>+</sup> channels
    - cardiac, 443
    - K<sup>+</sup> current
      - delayed rectifier, 445–54
- Pravastatin
  - and Alzheimer's disease, 573
- Pregnenolone-16 $\alpha$ -carbonitrile, 7, 12
- Prepulse inhibition (PPI), 271
- Presenilin(s) (PS)
  - and  $\gamma$ -secretase, 557–58, 559, 560–61, 563, 574
  - and Alzheimer's disease, 550
  - proteins regulating, 559
- Presynaptic homeostasis
  - and dopamine transporter (DAT)-KO mice, 264–65
- Prion disease, 534
- Pro-prodrug
  - and diazeniumdiolateds, 604
  - and erectile dysfunction, 603
- Progesterone, 8
  - and St. John's wort, 479
- PROLI/NO, 588
  - and cerebral vasospasm, 598, 604
  - and erectile response, 603
- Prostaglandin E (PGE), 84–85
- Prostaglandin transporter (PGT), 641
- Prostaglandins
  - and the aryl-hydrocarbon receptor (AhR), 319–20
  - and aspirin, 465
  - and mucosal integrity, 102
- Prostate cancer
  - and the Physicians' Health Study-II, 111
- Protease(s)
  - caspase 3-like, 213
  - intramembrane, 557
- Protein kinase
  - and mammalian dopamine

- transporters (DATs), 527
- Protein kinase A (PKA)  
and mammalian dopamine  
transporters (DATs), 527
- PKA phosphorylation  
of  $I_{Ks}$ , 451, 452
- Protein kinase C (PKC), 209,  
210, 211, 320, 640  
and ALP analogs, 213  
and mammalian dopamine  
transporters (DATs), 527  
and NMDA receptors  
(NMDARs), 344  
signaling pathway, 251–52,  
253
- Protein phosphatase 1 (PP1),  
452
- Protein tyrosine kinase  
(PTK), 345
- Protein(s), 381  
and  $\beta$ -secretase, 552  
and  $\gamma$ secretase, 559–60  
and  $\gamma$ -secretase, 574  
and 17AAG, 205  
adn telomerase, 369  
and the antioxidant  
response element (ARE),  
233, 237, 239, 240–46  
apoptosis specific protein  
(ASP), 533  
binding  
and the blood-brain  
barrier, 630  
cap'and'collar (CNC)  
proteins, 243, 246  
cellular retinoic acid  
binding proteins  
(CRABPs), 58  
CYP, 149–65  
cystic fibrosis  
transmembrane regulator  
protein (CFTR), 637  
decapentaplegic (*Smad*),  
82  
diazeniumdiolated  
and angioplasty, 591–92  
and diazeniumdiolates, 604  
in the diet, 18  
and diseases, 534  
and dopamine transporter  
(DAT), 527, 535  
and dopamine transporter  
(DAT)-1, 530, 531, 532  
and the endoplasmic  
reticulum, 338–39  
extracellular matrix (ECM)  
proteins, 73, 75, 77, 78,  
82, 85  
FKHR, 57  
flexibility  
and computer-aided drug  
design, 31–41  
G-protein(s), 381  
coupling, 399  
and dopamine  
transporter (DAT)-KO  
mice, 265  
G-protein coupled  
receptors (GPCRs),  
381, 383, 390, 394  
and gene therapy, 413–32  
glucocorticoid receptor  
interacting protein  
(GRIP1), 55  
HERG, 445  
hsp90, 310  
interactions with, 37  
iron transporting, 645  
Kelch-licke-ECH-  
associated protein 1  
(Keap 1), 246, 247, 251,  
252, 253  
kinases  
pilot studies on, 35  
and lipopolysaccharide  
(LPS), 612, 613, 614,  
616–17, 621–22  
liver microsomal synthesis,  
6  
Maf  
and the antioxidant  
response element  
(ARE), 240, 242,  
243–45, 247, 253  
microtubule-associated  
proteins (MAPs), 130,  
132–33  
nitric oxide synthase  
(NOS), 84  
Nrf2  
and the antioxidant  
response element  
(ARE), 233, 240–43,  
244, 245, 246, 247,  
248, 249, 251, 253
- PDZ  
and NMDA receptors  
(NMDARs), 335, 337,  
340, 341, 342, 343,  
348, 349  
polyamine-modulated  
factor-1 protein (PMF-1),  
246  
polypyrimidine  
tract-binding  
protein-associated  
splicing factor (PSF), 62  
prenylation, 215  
proline-rich nuclear  
receptor coregulatory  
proteins (PNRC), 57–58  
and proteasome, 214  
and reactive nitrogen oxide  
species (RNOS), 98  
receptor interacting protein  
140 (RIP140), 60, 61–62,  
63, 64  
and regulation of  
antioxidant response  
element (ARE), 245–46  
of retinoic acid receptors  
(RARs) and retinoid X  
receptors (RXRs), 51  
signaling, 616  
and statins, 109  
structural fluctuations in,  
31  
and synaptic transmission,  
523  
and telomerase, 359–60,  
363

- telomere binding, 361  
telomeric, 362  
that interact with NMDA receptors (NMDARs), 337–38, 350  
thyroid hormone receptor interacting protein I (TRIP1), 56  
thyroid hormone receptor (TR) associate protein 200 (TRAP220), 56  
thyroid hormone receptor uncoupling protein (TRUP), 62  
and TLRs, 614–15, 616  
TRF-1, 362  
tyrosine hydroxylase (TH) and dopamine transporter (DAT)-KO mice, 264, 265  
See also Amyloid  $\beta$ -protein ( $A\beta$ ); P-glycoprotein
- Proteolysis  
intramembrane, 556–57  
Proteasome, 214  
PS1, 558, 559  
and Alzheimer's disease, 550, 554–55, 561  
PS2, 558, 559  
and Alzheimer's disease, 550, 554–55, 561  
PS-341, 214  
Psychiatric disorders  
and the blood-brain barrier, 632  
Psychology  
experimental  
Psychostimulants  
and attention-deficit hyperactivity disorder (ADHD), 271  
and dopamine transporter (DAT)-KO mice, 268–69, 270, 271  
in norepinephrine transporter (NET)-KO mice, 274  
and serotonin transporter (SERT)-KO mice, 273
- Public health  
agencies  
and risk assessment/management  
procedures, 177  
and hormesis, 187, 191  
Pulmonary hypertension  
and diazeniumdiolates, 600–1  
Pure Food and Drugs Act of 1906, 466, 467  
Pyrazole  
and human colon cell lines, 164  
Pyridine, 17  
PYRRO/NO, 588, 589, 603  
and hepatocarcinogens, 603–4  
Pyrrolidinedithiocarbamate (PDTCT), 244
- Q**
- QRS complex  
on the ECG, 442–43  
QT  
acquired long QT syndrome, 443  
dynamics  
and sildenafil citrate, 112  
interval  
on the ECG, 442, 443  
prolongation of, 441, 443, 449, 453, 454  
long QT syndrome  
congenital, 449  
prolongation, 453  
and drugs, 444  
Quercetin  
inhibits CYP3A4, 162  
Quetiapine (Seroquel), 551  
Quinidine, 288, 444, 448  
and drug metabolism, 15–16
- Quinones  
and DA, 528
- R**
- R115777, 217–18  
Raclopride, 270  
and dopamine transporter (DAT)-KO mice, 271  
RAD001, 212  
Radiation, 73, 209  
and germ cell apoptosis, 136  
and the hormetic hypothesis, 192  
interest in low-dose stimulation, 192  
risk  
extrapolation model of, 486  
Ralitrexed, 202  
Rapamune, 199, 211–12  
Rapamycin, 199, 211–12  
mammalian target of rapamycin (mTOR), 211  
Reactive nitrogen oxide species (RNOS), 97–98  
Reactive oxygen species (ROS), 76, 79, 80, 81, 84, 85, 184  
and dopamine, 528, 529, 532  
Receptor-associated cofactor 3 (RAC3), 55  
Receptor interacting protein 140 (RIP140), 60, 61–62, 63, 64  
Receptor mediated transport (RMT), 629, 631, 634, 635, 644–45  
Receptor-mediated transport (RMT), 631  
Receptor(s)  
adrenergic, 381–404  
flexibility  
and protein-ligand interactions, 31  
NMDA, 335–50

- scavenger  
and the blood-brain  
barrier, 646-47  
Toll-like receptors (TLRs),  
609-22
- Reductase  
azo-link, 3-4
- Regulatory agencies  
and risk assessment, 176  
and risk assessment/  
management procedures,  
177
- Regulatory statutes  
Federal, 466-67
- Relaxed complex methods  
to discover ligands, 40-41
- Remediation technology, 192
- Renal epithelial tumor  
and *MDR1*  
polymorphisms, 299
- Renin  
renin-angiotensin-  
aldosterone pathway,  
107
- Repolarization  
cardiac, 451, 453-54  
and HERG channels,  
445  
and  $I_{Ks}$ , 450  
and cardiac electrical  
excitation, 442  
cellular, 441, 450,  
453-54  
disruption of, 449  
ventricular, 449
- Reserpine  
and CYP3A5, 164
- Respiratory difficulties  
and Alzheimer's disease,  
546
- Respiratory tissue  
and vinyl acetate exposure,  
511-12
- Respiratory tract  
cytochrome P450 in, 150,  
151-58, 164
- Restenosis  
after angioplasty, 585,  
590-93  
and nitric oxide (NO)  
delivery systems, 105  
reducing, 104
- Restriction fragment length  
polymorphism (RFLP),  
398
- Retinaldehyde, 47
- Retinoic acid (RA)  
active ingredient of vitamin  
A, 47-48  
and the aryl-hydrocarbon  
receptor (AhR), 320  
nuclear receptors for,  
48-49  
retinoic acid response  
elements (RAREs), 49,  
51, 52
- Retinoic acid receptors  
(RARs), 47  
and the aryl-hydrocarbon  
receptor (AhR), 320, 321  
coactivators of, 53-59  
coregulators of, 47, 51-64  
corepressors of, 59-62  
domain features of, 49-50  
and the retinoic acid (RA)  
receptor family, 48-49
- Retinoid X receptors (RXRs),  
47  
coactivators of, 53-59  
coregulators of, 47, 51-64  
corepressors of, 59-62  
domain features, 49-50  
and the retinoic acid (RA)  
receptor family, 48, 49
- Retinoid(s)  
and the aryl-hydrocarbon  
receptor (AhR), 320-21  
receptors, 47-64
- Retroviral vector(s)  
in clinical trials, 429-30  
development and  
production, 419-22  
and gene therapy, 414,  
417-24  
properties of, 431
- Retroviruses  
structure and replication,  
417-19  
and transduction, 422-24
- Rhabdovirus family, 422
- Rheumatoid arthritis, 73, 85
- Rho  
and statins, 108, 109
- Ribozymes  
and telomerase, 363, 367
- Rifampicin  
and drug metabolism, 16
- Rifampin, 287, 288, 289
- Risk  
assessment, 175  
cancer and noncancer  
harmonization of,  
175, 189-91  
carcinogen, 188-89, 486  
governmental procedure,  
177  
and hormesis, 184,  
186-92  
non-cancer, 193  
non-carcinogen, 188  
paradigms, 176  
communication  
and hormesis, 191-92  
evaluation  
AFB1, 494  
carcinogenic, 486
- Risperidone (Risperdal), 551
- Ritonavir, 297, 639
- Rivastigmine (Exelon)  
and Alzheimer's disease,  
551
- RNA  
hTR RNA template, 359,  
363, 365, 367  
and lentiviral vectors, 420,  
424  
mRNA and adenoviral  
vectors, 424  
and retroviral vectors,  
417-19, 420, 421  
and telomerase, 360

- RO-32-0432, 251  
 Rohitukine, 207  
 Rotenone, 529  
   and cell death, 533  
 Rusch, Dr. Harold, 2  
 RXT ER retention motif,  
   338–39, 340
- S**
- S-nitroso-albumin, 101  
 S-nitroso-captopril, 102  
 S-nitroso-diclofenac, 105  
 S-nitroso-glutathione, 101  
 S-nitroso-N-acetylpenicillamine,  
   101  
 S-nitroso-nonsteroidal  
   anti-inflammatory drugs  
   (NSAIDs), 105  
 S-nitrosothiols  
   and nitric oxide (NO),  
   101–2  
 Salicin, 465  
 Saquinavir, 297  
   and grapefruit juice, 163  
 Sarcomas, 202  
 Saroidosis, 73  
 SB202190, 249  
 SB203580, 249, 250, 251  
 Scavenger receptors  
   and the blood-brain barrier,  
   646–47  
 SCH23390, 270  
   and dopamine transporter  
   (DAT)-KO mice, 271  
 SCH66336, 217  
 Schizophrenia, 261, 336  
   and adrenergic receptor  
   polymorphisms (ARPs),  
   399, 400  
   and dopamine, 270, 522  
 Sclerosis  
   systemic, 73  
 $\alpha$ -Secretase  
   enhancement of activity of,  
   571–72  
 $\beta$ -Secretase, 571  
   cell biology of, 554  
   explained, 548  
   inhibition of, 552–56, 573  
   protease biochemistry of,  
   552–53  
   strategies to identify  
   inhibitors of, 555–56  
   substrate specificity of,  
   554–55  
 $\gamma$ -Secretase, 550, 574  
   explained, 548  
   inhibition of, 556–64, 573  
   inhibitors  
     and A $\beta$ , 561–64  
   as a multi-protein complex,  
   559–60  
   and nonsteroidal  
   anti-inflammatory drugs  
   (NSAIDs), 574–75  
   and presenilin, 557–58,  
   559, 560–61, 574  
 Seizures  
   and the blood-brain barrier,  
   632  
 Selegiline  
   and Alzheimer's disease,  
   552  
 Self-inactivating vectors  
   (SIN), 419  
   and lentiviral vectors, 420  
 Selye, Hans, 7  
 Senescence  
   cell, 373  
   at the telomeres, 362  
 Sensitivity analysis  
   systemic, 34–35, 41  
 Sensory experience  
   and synaptic NMDA  
   receptors (NMDARs),  
   346  
 Ser 49, 382, 383, 384–85  
 Serine, 215  
   serine/threonine kinase  
   antagonists, 207–10  
 Serotonin, 276, 277, 316–17  
   and amphetamine, 267  
   and attention-deficit  
   hyperactivity disorder  
   (ADHD), 271  
   and *C. elegans*, 523, 524  
   and cocaine responses,  
   269  
   and dopamine transporter  
   (DAT)-KO mice, 270  
   and dopaminergic  
   hyperactivity, 270  
   and locomotion, 272  
   and psychostimulants, 278  
 serotonin transporter  
   knockout (SERT-KO)  
   mice, 272–74, 275,  
   276–77, 278  
 serotonin transporters  
   (SERT), 261, 262, 268,  
   269  
 Sertoli cell(s), 128–29  
   and 2,5-hexanedione  
   (2,5-HD), 126, 136  
   and cytoplasmic dyneins,  
   133  
   ectoplasmic  
     specializations, 133  
   and germ cells, 135  
   and kinesin, 133  
   microtubule-dependent  
   transport, 139  
   microtubules, 140–41  
   and SCF, 137  
   and testicular atrophy, 131  
 Sertraline  
   and St. John's wort, 479  
 Serum amyloid-P (SAP),  
   564–65  
 Severe combined  
   immunodeficiency-X1  
   (SCID-X1)  
   and gene therapy, 429  
 Shock, 612  
   agent responsible for, 610  
 Signal transduction  
   and the aryl-hydrocarbon  
   receptor (AhR), 309–11  
   and cancer treatments,  
   199–220

- and the endotoxin receptor, 616–17
- and tyrosine kinase, 613
- Signaling pathways
  - and the antioxidant response element (ARE), 246–52, 253
- Sildenafil (Viagra), 112–13, 444, 601, 603
- Silencing mediator for retinoid and thyroid-hormone receptors (SMRT), 59–60, 62
- Simian immunodeficiency virus (SIV), 423
- Simulation methods
  - and drug design, 31–32
- Simvastatin, 109, 572
- Single nucleotide polymorphisms (SNPs), 108, 382, 386, 390, 392, 393, 394–95, 398, 399
  - drawbacks of, 101
  - intravenous, 100
  - and *MDR1* gene, 289, 292, 293–94, 297, 299, 300
  - and penile erections, 113
- Sirolimus, 199, 211–12
- Skin cancer
  - and ozone pollution, 192
- Small intestine
  - cell types in, 159
  - cytochrome P450 in, 151, 161–63
- Small unique nuclear receptor corepressor (SUN-CoR), 62
- Smokers, 19
  - and nasal tumors, 151
  - See also Cigarette(s)
- Smoking
  - See Cigarette(s); Smokers
- Sodium (Na)
  - Na<sup>+</sup> channels, 448
  - and cardiac electrical excitation, 442, 443
- Sodium nitroprusside (SNP) and nitric oxide (NO), 99
- Solvent models
  - and free energy calculations, 32, 36–38, 41
- Sotalol (Betapace), 444, 447
- SPACE trial, 111
- SPER/NO
  - and angioplasty, 591
- Spermatogenesis, 129, 133
  - and apoptosis, 134
  - and GnRH agonist, 138
  - and Sertoli cells, 141
  - and the Steele-Dickie mouse, 137–38
- Spermine, 587, 588, 591
- Spermatogenesis, 137
  - and Sertoli cell microtubules, 140
- Spinocerebellar Ataxias, 534
- Spumaviruses
  - and gene therapy, 418
- St. John's wort, 288, 479, 482
  - and depression, 481
  - and drug metabolism, 16
- Statins, 108–9
  - and Alzheimer's disease, 573
- StatV
  - $\beta$ -secretase inhibitor, 555–56
- Staurosporine, 251
  - 7-OH, 199, 209–10
- Stem cell factor (SCF), 136–38
- Stem cell gene therapy, 430
- Stent
  - in balloon angioplasty, 590
  - nitric oxide (NO)-releasing, 592
- Steroid(s)
  - and the aryl-hydrocarbon receptor (AhR), 319–20
  - hormones
    - and cigarette smoking, 17
- hydroxylation of, 12
- metabolism of, 9–10
- and microsomal enzymes, 7, 8
- steroid receptor coactivator (SRC), 53, 54, 55
- STI-571
  - and cancer treatment, 199, 200, 202, 219
- Stilbene, 453
- Stomach
  - cancer, 160–61
  - cell types in, 159
  - cytochrome P450 in, 151, 160–61
- Streptavidin
  - and binding affinities, 37
- Stress
  - and HSV-1 infection, 428
  - and learning performance, 185
- Stroke
  - and aspirin, 465
  - and cerebral vasospasm, 598
  - and nitric oxide (NO), 98
- Structure/function claims and dietary supplements, 468
- Styrene oxide, 488, 489
- SU0020, 204
- SU101, 203–4
- SU5416, 204
- Substantia nigra
  - of MPTP-treated dopamine transporter (DAT)-KO mice, 268
  - and Parkinson's disease, 529
- Substantia nigra pars compacta (SNpc)
  - dopamine neuronal death, 529
  - and Parkinson's disease, 528
- Subunit assembly
  - in the endoplasmic

- reticulum, 338–39  
and NMDA receptors (NMDARs), 336–37
- SUGI, 56
- Sulfhydryl group(s)  
and the antioxidant response element (ARE), 235, 246, 252
- Sulforophane (Sul), 248
- Sulfur amino acid deprivation (SAAD), 250
- Sulindac sulfate  
and A $\beta$ 42, 563–64
- Superoxide ion  
and Parkinson's disease, 529
- Superoxide radical, 100  
and dopamine, 528  
and nitric oxide (NO), 98
- Survival  
and lipopolysaccharide (LPS) sensitivity, 621
- SWI/SNF genes, 56
- Sympathetic nervous system stimulation  
and sudden cardiac death, 453
- Synapse  
and NMDA receptors (NMDARs), 335, 336, 340, 341, 342–50  
silent synapse hypothesis, 336
- Syntaxin  
and dopamine transporter (DAT)-1, 530–31
- $\alpha$ -Synuclein, 527, 531, 534, 535
- Systematic sensitivity analysis  
systematic, 34–35, 41
- Systole, 442
- T**
- T cells  
and gene therapy, 429, 430
- T wave  
on the ECG, 442, 443, 449, 454
- TAB1, 616
- TAB2, 616
- Tachyarrhythmias  
supraventricular, 443
- Tachyphylaxis, 393–94
- Tacrolimus, 294  
and diltiazem, 639
- TAK1, 616
- Tangeretin, 13
- Tarceva<sup>TM</sup>, 199, 203
- Taurine, 77, 78, 79, 84
- Taxol, 209  
and spermtogenesis, 140
- Taylor's series expansion, 34–35
- Teas  
and aryl-hydrocarbon receptor (AhR) ligands, 313
- Telomerase, 359–74, 373  
inhibition of, 360, 363–73
- Telomere(s)  
capping, 362  
inhibition and disruption, 359–74  
structure and function of, 360–62  
targeting of, 368–73
- Temozolamide, 210
- Terbutaline, 395, 396
- Terfenadine (Seldane), 443, 444, 447, 448  
and grapefruit juice, 163
- tert*-butylhydroquinone (*t*BHQ), 236, 237, 238, 239, 240, 242, 244, 248, 250, 251
- Testicular atrophy, 126, 129  
persistence of, 137, 138  
and Sertoli cells, 131  
therapy for, 138–39
- Testicular injury  
and 2,5-hexanedione (2,5-HD), 125–41  
toxicant-induced, 139
- Testosterone  
hydroxylation of, 8–10, 22  
and testicular atrophy, 138, 139
- 2,3,7,8-Tetrachlorodibenzo-*p*-dioxin (TCDD)  
and the aryl-hydrocarbon receptor (AhR), 309, 310, 311, 313, 316, 317–18, 319–20, 321  
and CYPs, 154, 156–57  
and human colon cell lines, 164
- Tetraethyl ammonium (TEA), 448
- Tetrahydroaminoacridine (Cognex)  
and Alzheimer's disease, 551
- Tetrahydrobenzodiazepine, 216
- Tetrahydrobiopterin  
and nitrate tolerance, 101
- Tetrapeptide, 215
- Tetrapyroles  
and the aryl-hydrocarbon receptor (AhR), 318–19
- Thalidomide  
crisis of 1962, 466
- Theophylline  
and cigarette smoking, 18  
oxidative metabolism of, 18
- Therapeutic agents  
and CYPs, 150  
and nasal tumors, 151
- Therapeutics  
complementary and alternative, 463–82
- Thermodynamic  
cycle-perturbation method  
and free energy calculations, 32–33



- Thin-layer chromatography (TLC)  
and *C. elegans*, 524  
Thiocyanate toxicity, 99  
Thiols  
and nitrate esters, 100  
and nitrate tolerance, 101  
Thioredoxin, 253  
Thioridazine (Mellaril), 443, 444  
Thr164, 388, 389, 390, 395  
Thr623, 448  
Threonine, 212  
serine/threonine kinase antagonists, 207-10  
Threshold mechanisms  
and carcinogens, 487-91  
Thrombin, 103  
Thrombogenicity  
of medical devices, 593-96  
Thrombosis, 108  
and nitric oxide (NO)  
delivery systems, 105  
therapy for, 102  
Thromboxane  
and NCX-4016, 104  
Thyroid hormone receptor  
associate protein 200 (TRAP220), 56  
Thyroid hormone receptor  
interacting protein I (TRIP1), 56  
Thyroid hormone receptor  
uncoupling protein (TRUP), 62  
Thyroid response element (TRE), 59  
Tissue factor (TF)  
and CYPs, 150, 104  
Tissue plasminogen activator (tPA), 204  
Tissues  
extrahepatic, 165  
and CYPs, 150, 157  
Tobacco smoke  
environmental, 498  
and nasal CYPs, 157  
See also Cigarette(s)  
Toll/IL-1 receptor/resistance (TIR domain), 614-15, 616  
Toll-like receptor(s) (TLR), 609-22  
evolution of, 614-15  
structure, 615-16  
TLR1, 622  
TLR2, 613, 615, 616, 617  
TLR3, 613, 615  
TLR4, 613, 616, 617  
and changes in  
chromatin structure, 615  
and lipopolysaccharide (LPS), 614, 615  
mutations at, 617-18  
signaling  
pharmacological blockade of, 621-22  
TLR5, 613  
TLR6, 622  
TLR7, 622  
TLR8, 622  
TLR9, 613, 617  
TLR10, 622  
Topotecan, 202  
Tourette syndrome, 261  
Toxic substances  
at low doses, 191  
low doses of, 177  
Toxicant(s)  
and CYPs, 150  
exposure  
and germ cell apoptosis, 136  
risk assessment of, 150, 151  
Toxicity  
chemical, 165  
and CYPs, 150  
developmental, 154  
and diazeniumdiolates, 603-4  
 $\gamma$ -diketone-induced, 126  
of nonsteroidal  
anti-inflammatory drugs (NSAIDs), 102  
respiratory, 156  
single nucleotide polymorphisms (SNP), 99  
systemic  
and lung fibrosis  
treatment, 74, 80, 84, 86  
xenobiotic, 152, 156  
Toxicological literature  
hormesis in, 179  
Toxicological studies  
and hormesis, 177  
Toxicology  
community  
and hormesis, 176-77  
definition of, 175  
definition should be changed, 176  
and the dose-response revolution, 176-77  
and hormesis, 175, 193  
Toxins  
environmental, 535  
immune response to, 609-22  
TPA, 251  
TPA-response element (TRE)  
and the antioxidant response element (ARE), 239, 240, 242  
Trachea  
See Respiratory tract  
TRAF6, 616  
Trans Golgi network (TGN)  
and NMDA receptors (NMDARs), 341  
Transcription  
and the antioxidant response element (ARE), 233, 235, 236, 237, 240-46, 247, 248, 249, 250, 251-52, 253  
Transcriptional intermediary factor I (TIFI), 55

- Transduction  
   adeno-associated viral (AAV) vector, 416–17  
   and adenoviral vectors, 426–27  
   and HSV-1 vector, 428–29  
   and retroviruses, 422–25, 430  
 Transferrin-receptor 1 (Tf-R1), 644  
 Transferrin-receptor 2 (Tf-R2), 644–45  
 Transforming growth factor- $\beta$ , 77–82, 83, 85, 87  
 Transport systems  
   nucleoside  
     and the blood-brain barrier, 642–43  
 Transporter(s)  
   anion influx and efflux  
     and the blood-brain barrier, 641–42  
   and the blood-brain barrier, 631  
   large neutral amino acid  
     and the blood-brain barrier, 643–44  
 Trastuzumab, 206–7  
 Trauma, 73  
 Trichloroethylene  
   and carcinogenesis, 486, 488  
 Troleandomycin, 160  
 Trypsin, 35  
 Tryptamine  
   and the aryl-hydrocarbon receptor (AhR), 317, 321  
 Tryptophan (Trp)  
   and the aryl-hydrocarbon receptor (AhR), 314, 321  
   and aryl-hydrocarbon receptor (AhR) ligands, 316–17  
   and dopamine transporter (DAT)-KO mice, 270  
 Trp64, 396, 397  
 Tubulin, 140  
   and testicular injury, 129–32, 139  
 Tumor necrosis factor (TNF), 204  
   and endotoxicity, 612  
   and lipopolysaccharide (LPS), 617  
   mRNA translation, 616  
   and TLR4, 615  
   and TLRs, 617  
   TNF- $\alpha$ , 79, 80, 83  
     apoptosis induced by, 104  
     and Bryo 1, 211  
     and NCX-4016, 104  
 Tumorigenesis  
   and CYPs, 154  
 Tumor(s)  
   and 17AAG, 205  
   and CCI-779, 212  
   cell population doublings, 362  
   cells  
     and edelfosine, 213  
     and MAPK, 212  
     and PS-341, 214  
     and SCH66336, 217  
   and cetuximab, 207  
   and farnesyl transferase inhibitors, 215  
   and flavopiridol, 208–9  
   formation  
     and hormesis, 183–84  
     and vinyl acetate, 512  
   vinyl acetate exposure, 511  
   growth  
     and anti-cancer agents, 192  
     inhibition of, 200  
     low-dose enhancing, 186  
   and hormetic dose response, 193  
   incidence  
     and cell cycle arrest, 490  
     and DNA adducts, 498  
     and DNA repair enzymes, 490  
   nasal, 151  
   and rapamycin, 211  
   rates  
     and apoptosis, 491  
   and signal transduction inhibitors, 219  
   and STI-571, 202  
   and trastuzumab, 205–7  
   and UCN-01  
   and vinyl acetate exposure, 504–5  
   and ZD 1839, 202  
 Twins  
   and drug metabolism, 20  
 Type II cells, 151–52  
 Tyr652, 448  
 Tyrosine, 212  
   and NMDA receptor (NMDAR)  
     internalization, 349, 350  
 Tyrosine hydroxylase (TH)  
   and *C. elegans*, 524  
   and dopamine transporter (DAT)-KO mice, 264, 526–27  
   inhibition, 266  
 Tyrosine kinase  
   Ber-Abl, 200  
   c-Kit, 136–37  
   inhibitors, 200–7  
   in lipopolysaccharide (LPS) signaling, 613  
  
 U  
 U0126  
 UCN-01, 199, 209–10  
 UDPGT\*01  
   and the aryl-hydrocarbon receptor (AhR), 318  
 UGT\*01  
   and the aryl-hydrocarbon receptor (AhR), 318  
 Ulcers  
   and gastrointestinal

- toxicity, 102  
 University of  
   Wisconsin-Madison  
   Allan H. Conney at, 2  
 Urinary tract infection (UTI), 476  
 U.S. Environmental Protection Agency (EPA), 177  
 U.S. Federal Drug Administration (FDA), 177  
 UV irradiation  
   and HSV-1 infection, 428
- V**
- V-PYRRO/NO  
   heptaprotective, 603  
 Vaccines, 466  
   reduced the number of deaths, 464  
 Val625, 448  
 Valsartan, 107  
 Vardenafil  
   and penile erections, 113  
 Vascular disease  
   and chelation therapy, 471  
 Vascular endothelial growth factor (VEGF), 204  
 Vascular grafts  
   and diazeniumdiolates, 593-94, 595  
 Vasodilation  
   and AT-1 antagonist, 107  
   and calcium channel blockers (CCBs), 106  
   and nebivolol, 108  
   and nitric oxide (NO), 98  
 Vasorelaxation  
   and nitrates, 99  
 Vasospasm, 596, 598-99  
 Vegetable(s)  
   and aryl-hydrocarbon receptor (AhR) ligands, 313  
   and cancer risk, 238  
   diet, 19  
 Veins  
   and beta ( $\beta$ )-blockers, 107-8  
 Venodilation  
   and beta ( $\beta$ )-blockers, 107-8  
 Ventricle(s)  
   and cardiac electrical excitation, 441-42  
   left ventricle (LV)  
     and intravenous nitroglycerin, 100  
 Verapamil, 639  
   and grapefruit juice, 163  
 Vesicles  
   and NMDA receptors (NMDARs), 341  
 Vesicular monoamine transporter 2 (VMAT2)  
   and *C. elegans*, 524  
 Vesicular monoamine transporters (VMATs)  
   and *C. elegans*, 524  
 Viagra, 444  
 Vinblastine, 638-39  
 Vinyl acetate  
   carcinogenicity studies  
     with inhalation exposure, 505-6  
   carcinogenicity studies  
     with oral exposure, 501-5  
   epidemiological studies of carcinogenicity of, 506-7  
   as a genotoxic carcinogen, 485, 486, 499-513  
   inhalation exposure to, 508  
   metabolism and genotoxicity of, 507-8  
   occupational exposures to, 513  
   oral exposure to, 501-5  
   practical threshold for carcinogenesis, 508-13  
 Viral infections, 22  
 Viral vectors
- in clinical trials, 429-30  
   gene therapy with, 413-32  
   integrating and nonintegrating, 414  
 Virus(es)  
   and gene therapy, 413-32  
   helper, 414-15  
 Visna, 423  
 Vitamin A  
   and retinoic acid (RA), 47-48, 49  
 Vitamin C  
   and Alzheimer's disease, 552  
   and LDL oxidation, 110  
   and the Physicians' Health Study-II, 111  
   and S-nitrosothiols, 101  
 Vitamin D receptor (VDR), 56  
 Vitamin E  
   and Alzheimer's disease, 552  
   and cardiovascular events, 111  
   and the Physicians' Health Study-II, 111  
 VMAT2, 264, 267, 277
- W**
- Watercress, 19  
 West Nile fever, 464  
 Willow tree  
   therapeutic benefits of, 464  
 Wine  
   and cardiovascular disease, 192  
 Withering, William, 466  
 Wood dust  
   and nasal tumors, 151  
 Wortmannin, 250
- X**
- XE991, 453  
 Xenobiotic(s)  
   compounds

and CYPs, 150  
and cytochrome P450  
enzymes, 149-50  
and the respiratory tract,  
151  
enzyme induction by, 234,  
235-38  
metabolic activation of,  
152  
metabolism, 7, 8, 13-22  
and CYPs, 149-65  
G.I. tract, 158-59  
and hydrocarbons,  
17-18

metabolizing enzymes  
and aryl-hydrocarbon  
receptor (AhR) ligands,  
309, 310, 323  
neurotoxic, 300  
and P-glycoprotein, 285,  
286, 298  
and the small intestine,  
161  
study of the adverse effects  
of, 175  
xenobiotic response  
element (XRE), 234, 235,  
238, 250

## Y

Yerkes, Robert, 185  
Yerkes-Dadson Law, 185  
Yohimbine, 113

## Z

ZD 1839  
and cancer treatment, 199,  
202-3  
Zoxazolamine, 6, 7, 13  
hydroxylase  
and cigarette smoking,  
17  
hydroxylation of, 14-15



## CUMULATIVE INDEXES

---

### CONTRIBUTING AUTHORS, VOLUMES 39-43

#### A

Adams JP, 42:135-63  
Allen JW, 39:151-73  
Allio T, 43:125-47  
Altman RB, 42:113-33  
Amara SG, 39:431-56  
Ambudkar SV, 39:361-97  
Anderson SP, 40:491-518  
Angers S, 42:409-35  
Aschner M, 39:151-73  
Atkinson AJ Jr, 41:347-66

#### B

Bagdassarian CK,  
41:661-90  
Baker RC, 39:127-50  
Balboa MA, 39:175-89  
Baldwin LA, 43:175-97  
Balsinde J, 39:175-89  
Barber DL, 42:527-52  
Barnes PJ, 42:81-98  
Bearss DJ, 43:359-79  
Bertaccini E, 41:23-51  
Beutler B, 43:609-28  
Blackburn TP, 40:319-34  
Blau HM, 40:295-317  
Bode-Böger SM, 41:79-99  
Böger RH, 41:79-99  
Blakely RD, 43:521-44  
Boekelheide K, 43:125-47  
Bogdanffy MS, 43:485-520  
Bolt HM, 43:485-520  
Borges K, 39:221-41  
Borjigin J, 39:53-65  
Bortner CD, 42:259-81  
Bouvier M, 42:409-35  
Bradfield CA, 40:519-61  
Branchek TA, 40:319-34  
Breyer MD, 41:661-90

Breyer RM, 41:661-90  
Broder S, 40:97-132  
Brown JH, 40:459-89  
Brunton LL, 41:751-73  
Burgan ASV, 40:1-16  
Burke MD, 41:297-316

#### C

Calabrese EJ, 43:175-97  
Carlsson A, 41:237-60  
Carlsson ML, 41:237-60  
Chan PLS, 41:625-59  
Changeux J-P, 40:431-58  
Choudhuri S, 39:267-94  
Caron MG, 43:261-84  
Chun J, 41:507-34  
Cidlowski JA, 42:259-81  
Clancy CE, 43:441-61  
Coles P, 41:175-202  
Collins MD, 39:399-430  
Conney AH, 43:1-30  
Contos JJA, 41:507-34  
Corringer P-J, 40:431-58  
Corton JC, 40:491-518  
Coyle JT, 42:165-79

#### D

Dalton TP, 39:67-101  
Davis KL, 41:203-36  
Debouck C, 40:193-208  
de Boer AG, 43:629-56  
Defer N, 41:145-74  
de Groat WC, 41:691-721  
Denhardt DT, 41:723-49  
Denison MS, 43:309-34  
Denker SP, 42:527-52  
Dennis EA, 39:175-89  
De Vries L, 40:235-71  
Dey S, 39:361-97

Ding X, 43:149-73  
Dingledine R, 39:221-41  
Doull J, 41:1-21  
DuBois RN, 42:55-80

#### E

Eichelbaum M, 43:285-307  
Elenko E, 40:235-71  
Elliott JD, 40:177-91  
Elsayed Y, 43:199-231  
Embree-Ku ME, 43:125-47  
Eudy JD, 42:181-208  
Evans WE, 41:101-21

#### F

Farquhar MG, 40:235-71  
Fernandez EJ, 42:469-99  
Finnell RH, 42:181-208  
Fischer T, 40:235-71  
Fleming SL, 43:125-47  
Flexner C, 40:651-76  
Fromm MF, 43:285-307  
Fu H, 40:619-49  
Fukushima N, 41:507-34

#### G

Gaillard PJ, 43:629-56  
Gainetdinov RR, 43:261-84  
Gelineau-van Waes J,  
42:181-208  
Giachelli CM, 41:723-49  
Gillette JR, 40:19-41  
Giri SN, 43:73-95  
Golding BT, 42:325-48  
Goodman JI, 42:501-25  
Goodwin B, 42:1-23  
Gottesman MM, 39:361-97  
Greenlee WF, 41:297-316  
Griffin RJ, 42:325-48

Gu Y-Z, 40:519-61  
 Guengerich FP, 39:1-17  
 Guyton KZ, 41:421-42

## H

Hall SJ, 43:125-47  
 Hammond HK, 39:343-60  
 Hanoune J, 41:145-74  
 Hardcastle IR, 42:325-48  
 Harris RA, 41:23-51  
 Hengstler JG, 43:485-520  
 Hickson ID, 41:367-401  
 Hobbs AJ, 39:191-220  
 Hogenesch JB, 40:519-61  
 Hogg N, 42:585-600  
 Holford NHG, 40:209-34;  
 41:625-59  
 Holm-Waters S, 41:237-60  
 Hook SS, 41:471-505  
 Houghten RA, 40:273-82  
 Hrycyna CA, 39:361-97  
 Hurley LH, 43:359-79

## I

Ignarro LJ, 43:97-123  
 Insel PA, 39:175-89, 343-60;  
 41:593-624  
 Ishii I, 41:507-34

## J

Javitch JA, 42:437-67  
 Johnson DG, 39:295-312  
 Johnson KJ, 43:125-47  
 Juliano RL, 42:283-323

## K

Kaminsky LS, 43:149-73  
 Kass RS, 43:441-61  
 Kedzierski RM,  
 41:851-76  
 Keefer LK, 43:585-607  
 Kenakin T, 42:349-79  
 Kensler TW, 41:421-42  
 Kim G, 43:199-231  
 Kim RB, 41:815-50  
 Kimelberg HK, 39:151-73  
 Kimko HC, 40:209-34

Kinsel JF, 43:463-84  
 Kitteringham NR,  
 41:443-70  
 Klaassen CD, 39:267-94  
 Klein PS, 41:789-813  
 Klein TE, 42:113-33  
 Kliever SA, 42:1-23  
 Kootstra NA, 43:413-39  
 Kramer RE, 39:127-50  
 Kurokawa J, 43:441-61  
 Kwon EJ, 43:125-47

## L

Law P-Y, 40:389-430  
 Lebedeva I, 41:403-19  
 Lee HC, 41:317-45  
 Lee SJ, 41:569-91  
 Lefer DJ, 40:283-94  
 Le Novère N, 40:431-58  
 Lesko LJ, 41:347-66  
 Li T-K, 41:53-77  
 Li X, 39:53-65  
 Liggett SB, 43:381-411  
 Lin JH, 41:535-67  
 Linden J, 41:775-87  
 Liu J, 39:267-94  
 Liu LF, 41:53-77  
 Loh HH, 40:389-430  
 Lolis E, 42:469-99  
 LoPachin RM, 39:151-73  
 Lu AYH, 41:535-67

## M

Maliakal P, 42:25-54  
 Mao GE, 39:399-430  
 Marnett LJ, 42:55-80  
 Martin E, 41:203-36  
 Masters SC, 40:619-49  
 McCammon AJ, 43:31-45  
 McEwen BS, 41:569-91  
 McGraw DW, 43:381-411  
 McLeod HL, 41:101-21  
 Means AR, 41:471-505  
 Melvin WT, 41:297-316  
 Meng X, 42:25-54  
 Metcalf B, 40:193-208  
 Michel JJ, 42:235-57

Moncada S, 39:191-220  
 Monga M, 43:199-231  
 Monteleone JPR,  
 40:209-34  
 Montfort WR, 41:261-95  
 Murad F, 41:203-36  
 Murray GI, 41:297-316  
 Myers SA, 41:661-90  
 Myers SJ, 39:221-41

## N

Nagata K, 40:159-76  
 Nagy SR, 43:309-34  
 Napoli C, 43:97-123  
 Nass R, 43:521-44  
 Negishi M, 41:123-43  
 Nemeroff CB, 41:877-906  
 Neu J, 42:381-408  
 Nguyen T, 43:233-60  
 Nilsson M, 41:237-60  
 Norbury CJ, 41:367-401  
 North RA, 40:563-80

## O

Oesch F, 43:485-520  
 Ohlstein EH, 40:177-91  
 O'Neill PM, 41:443-70  
 Otterness DM, 39:19-52  
 Owens MJ, 41:877-906  
 Ozawa CR, 40:295-317

## P

Park BK, 41:443-70  
 Pastan I, 39:361-97  
 Patel SR, 43:125-47  
 Peck CC, 40:209-34  
 Petralia RS, 43:335-58  
 Phiel CJ, 41:789-813  
 Pickett CB, 43:233-60  
 Plaa GL, 40:43-65  
 Pootoolal J, 42:381-408  
 Posner GH, 41:421-42  
 Post SR, 39:343-60  
 Powis G, 41:261-95  
 Puga A, 39:67-101  
 Prybylowski K, 43:335-58  
 Putney LK, 42:527-52



**R**

Ramachandra M, 39:361-97  
Ramos KS, 39:243-65  
Rana BK, 41:593-624  
Rasoulpour RJ, 43:125-47  
Redinbo MR, 42:1-23  
Rezler EM, 43:359-79  
Rittling SR, 41:723-49  
Rosenquist TH, 42:181-208  
Ruffolo RR Jr, 40:177-91

**S**

Sagi SA, 40:459-89  
Sah VP, 40:459-89  
Salahpour A, 42:409-35  
Sans N, 43:335-58  
Sausville EA, 43:199-231  
Schenk D, 43:545-84  
Schoenfeld HA, 43:125-47  
Schwab M, 43:285-307  
Scott JD, 42:235-57  
Seal RP, 39:431-56  
Seasholtz TM, 40:459-89  
Selkoe DJ, 43:545-84  
Sheiner L, 40:67-96  
Sherratt PJ, 43:233-60  
Shertzer HG, 39:67-101  
Shi L, 42:437-67  
Shiina T, 41:593-624  
Shoham M, 41:175-202  
Sibley DR, 39:313-41  
Small KM, 43:381-411  
Snyder SH, 39:53-65  
Springer ML, 40:295-317  
Standley S, 43:335-58

Starkov AA, 40:353-88  
Stauber A, 40:491-518  
Steimer J-L, 40:67-96  
Stein CA, 41:403-19  
Stein CM, 41:815-50  
Steinberg SF, 41:751-73  
Stout SC, 41:877-906  
Strassburg CP, 40:581-618  
Streit WJ, 39:151-73  
Straus SE, 43:463-84  
Subramanian RR, 40:619-49  
Sueyoshi T, 41:123-43  
Surprenant A, 40:563-80  
Svensson CI, 42:553-83  
Sweatt JD, 42:135-63  
Szumlanski CL, 39:19-52

**T**

Tateyama M, 43:441-61  
Taylor SL, 42:99-112  
Tedroff J, 41:237-60  
Thibonnier A, 41:175-202  
Thibonnier M, 41:175-202  
Thompson S, 43:125-47  
Trudell JR, 41:23-51  
Tsai G, 42:165-79  
Tukey RH, 40:581-618  
Turko IV, 41:203-36

**U**

Ulrich RG, 40:335-52

**V**

van der Sandt ICJ,  
43:629-56

Venter JC, 40:97-132  
Verma IM, 43:413-39

**W**

Walker CL, 39:295-312  
Wallace KB, 40:353-88  
Waring JF, 40:335-52  
Waters N, 41:237-60  
Watson RE, 42:501-25  
Wehrens XHT, 43:441-61  
Wei L-N, 43:47-72  
Weiner JA, 41:507-34  
Weinshilboum RM, 39:19-52  
Wenthold RJ, 43:335-58  
White RE, 40:133-57  
Whitlock JP Jr, 39:103-25  
Wong CF, 43:31-45  
Wong YH, 40:389-430  
Wood AJJ, 41:815-50  
Wright GD, 42:381-408

**X**

Xie H-G, 41:815-50

**Y**

Yaksh TL, 42:553-83  
Yamakura T, 41:23-51  
Yamazoe Y, 40:159-76  
Yanagisawa M, 41:851-76  
Yang CS, 42:25-54  
Yoshimura N, 41:691-721

**Z**

Zhang Z-Y, 42:209-34  
Zheng B, 40:235-71

## CHAPTER TITLES, VOLUMES 39-43

### Prefatory

#### PHARMACOLOGY

Targets of Drug Action	A Burgen	40:1-16
High-Throughput Screening in Drug Metabolism and Pharmacokinetic Support of Drug Discovery	RE White	40:133-57

#### TOXICOLOGY

Laboratory of Chemical Pharmacology, National Heart, Lung, and Blood Institute, NIH: A Short History	JR Gillette	40:19-41
Chlorinated Methanes and Liver Injury: Highlights of the Past 50 Years	GL Plaa	40:43-65
Central Role of Peroxisome Proliferator-Activated Receptors in the Actions of Peroxisome Proliferators	JC Corton, SP Anderson, A Stauber	40:491-518
Toxicology Comes of Age	J Doull	41:1-21
Induction of Drug-Metabolizing Enzymes: A Path to the Discovery of Multiple Cytochromes P450	AH Conney	43:1-30

### General Topics in Pharmacology and Toxicology

Hormesis: The Dose-Response Revolution	EJ Calabrese, LA Baldwin	43:175-97
Regulatory Mechanisms Controlling Gene Expression Mediated by the Antioxidant Response Element	T Nguyen, PJ Sherratt, CB Pickett	43:233-60

#### RECEPTORS

Genetic Regulation of Glutamate Receptor Ion Channels	SJ Myers, R Dingledine, K Borges	39:221-41
New Insights into Dopaminergic Receptor Function Using Antisense and Genetically Altered Animals	DR Sibley	39:313-41

5-HT <sub>6</sub> Receptors as Emerging Targets for Drug Discovery	TA Branchek, TP Blackburn	40:319-34
Nicotinic Receptors at the Amino Acid Level	P-J Corringer, N Le Novère, J-P Changeux	40:431-58
Pharmacology of Cloned P2X Receptors	RA North, A Surprenant	40:563-80
Lysophospholipid Receptors	N Fukushima, I Ishii, JJ Contos, JA Weiner, J Chun	41:507-34
Genetic Variations and Polymorphisms of G Protein-Coupled Receptors: Functional and Therapeutic Implications	BK Rana, T Shiina, PA Insel	41:593-624
Prostanoid Receptors: Subtypes and Signaling	RM Breyer, CK Bagdassarian, SA Myers, MD Breyer	41:661-90
Role of Osteopontin in Cellular Signaling and Toxicant Injury	DT Denhardt, CM Giachelli, SR Rittling	41:723-49
Molecular Approach to Adenosine Receptors: Receptor-Mediated Mechanisms of Tissue Protection	J Linden	41:775-87
Glutamatergic Mechanisms in Schizophrenia	G Tsai, JT Coyle	42:165-79
Drug Efficacy at G Protein-Coupled Receptors	T Kenakin	42:349-79
Dimerization: An Emerging Concept for G Protein-Coupled Receptor Ontogeny and Function	S Angers, A Salahpour, M Bouvier	42:409-35
The Binding Site of Aminergic G Protein-Coupled Receptors: The Transmembrane Segments and Second Extracellular Loop	L Shi, JA Javitch	42:437-67
Retinoid Receptors and Their Coregulators	L-N Wei	43:47-72
Trafficking of NMDA Receptors	RJ Wenthold, K Prybylowski, S Standley, N Sans, RS Petralia	43:335-58

## RENAL SYSTEM

- |   |                             |            |
|---|-----------------------------|------------|
| Pharmacology of the Lower Urinary Tract | WC de Groat,<br>N Yoshimura | 41:691-721 |
|---|-----------------------------|------------|

## SIGNAL TRANSDUCTION

- |  |                             |           |
|--|-----------------------------|-----------|
| Physiological Functions of Cyclic<br>ADP-Ribose and NAADP as Calcium<br>Messengers | HC Lee                      | 41:317-45 |
| Cellular Mechanisms for the Repression of<br>Apoptosis                             | CD Bortner,<br>JA Cidlowski | 42:259-81 |

## SYNAPTIC FUNCTIONS

- |  |  |            |
|--|--|------------|
| Inhibition of Nitric Oxide Synthase as a<br>Potential Therapeutic Target   | AJ Hobbs, A Higgs,<br>S Moncada                                | 39:191-220 |
| Redox Regulation of <i>c-Ha-ras</i> and<br>Osteopontin Signaling in Vascular<br>Smooth Muscle Cells: Implications in<br>Chemical Atherogenesis | KS Ramos   | 39:243-65  |
| Cyclins and Cell Cycle Checkpoints   | DG Johnson,<br>CL Walker                                       | 39:295-312 |
| The Regulator of G Protein Signaling<br>Family   | L De Vries, B Zheng,<br>T Fischer,<br>E Elenko,<br>MG Farquhar | 40:235-71  |
| Pharmacology of Selectin Inhibitors in<br>Ischemia/Reperfusion States  | DJ Lefer   | 40:283-94  |
| The Role of Rho in G Protein Coupled<br>Receptor Signal Transduction   | VP Sah,<br>TM Seasholtz,<br>SA Sagi, JH Brown                  | 40:459-89  |
| 14-3-3-Proteins: Structure, Function, and<br>Regulations   | H Fu,<br>RR Subramanian,<br>SC Masters                         | 40:619-49  |
| Molecular Psychology: Roles for the ERK<br>MAP Kinase Cascade in Memory  | JP Adams, JD Sweatt  | 42:135-63  |
- TRANSPORTERS
- |   |                                |           |
|---|--------------------------------|-----------|
| Compartmentation of G Protein-Coupled<br>Signaling Pathways in Cardiac Myocytes | SF Steinberg,<br>LL Brunton LL | 41:751-73 |
| AKAP-Mediated Signal Transduction   | JJC Michel, JD Scott           | 42:235-57 |

The Changing Face of the $\text{Na}^+/\text{H}^+$ Exchanger, NHE1: Structure, Regulation, and Cellular Actions	LK Putney, SP Denker, DL Barber	42:527-52
Monoamine Transporters: From Genes to Behavior	RR Gainetdinov, MG Caron	43:261-84
Genetic Polymorphisms of the Human MDR1 Drug Transporter	M Schwab, M Eichelbaum, MF Fromm	43:285-307
The <i>Caenorhabditis elegans</i> Dopaminergic System: Opportunities for Insights into Dopamine Transport and Neurodegeneration	R Nass, RD Blakely	43:521-44
The Role of Drug Transporters at the Blood-Brain Barrier	AG de Boer, ICJ van der Sandt, PJ Gaillard	43:629-56

## ENZYMES

Methylation Pharmacogenetics: Catechol O-Methyltransferase, Thiopurine Methyltransferase, and Histamine N-Methyltransferase	RM Weinshilboum, DM Otterness, CL Szumlanski	39:19-52
Regulation and Inhibition of Phospholipase $\text{A}_2$	J Balsinde, MA Balboa, PA Insel, EA Dennis	39:175-89
Human UDP-Glucuronosyltransferases: Metabolism, Expression, and Disease	RH Tukey, CP Strassburg	40:581-618
Tumor Cell Death Induced by Topoisomerase-Targeting Drugs	T-K Li, LF Liu	41:53-77
Phenobarbital Response Elements of Cytochrome P450 Genes and Nuclear Receptors	T Sueyoshi, M Negishi	41:123-43
Regulation and Role of Adenylyl Cyclase Isoforms	J Hanoune, N Defer	41:145-74
Regulation of CYP3A Gene Transcription by the Pregnane X Receptor	B Goodwin, MR Redinbo, SA Kliewer	42:1-23

Protein Allergenicity Assessment of Foods Produced Through Agricultural Biotechnology	SL Taylor	42:99-112
The Biochemistry and Physiology of S-Nitrosothiols	N Hogg	42:585-600
Telomere Inhibition and Telomere Disruption as Processes for Drug Targeting	EM Rezler, DJ Bearss, LH Hurley	43:359-79
CHEMICAL AGENTS		
The Pineal Gland and Melatonin: Molecular and Pharmacologic Regulation	J Borjigin, X Li, SH Snyder	39:53-65
Regulation of Gene Expression by Reactive Oxygen	TP Dalton, HG Shertzer, A Puga	39:67-101
Cytotoxicity of Short-Chain Alcohols Metallothionein: An Intracellular Protein to Protect Against Cadmium Toxicity	RC Baker, RE Kramer	39:127-50
Teratology of Retinoids	CD Klaassen, J Liu, S Choudhuri	39:267-94
The Clinical Pharmacology of L-Arginine	MD Collins, GE Mao	39:399-430
The Basic and Clinical Pharmacology of Nonpeptide Vasopressin Receptor Antagonists	RH Böger, SM Bode-Böger	41:79-99
Novel Effects of Nitric Oxide	M Thibonnier, P Coles, A Thibonnier, M Shoham	41:175-202
Inhibition of Carcinogenesis by Tea	KL Davis, E Martin, IV Turko, F Murad	41:203-36
Nitric Oxide-Releasing Drugs	CS Yang, P Maliakal, X Meng	42:25-54
2,5-Hexandione-Induced Testicular Injury	C Napoli, LJ Ignarro	43:97-123
	K Boekelheide, SL Fleming, T Allio, ME Embree-Ku, SJ Hall, KJ Johnson, EJ Kwon, SR Patel, RJ Rasoulpour, HA Schoenfeld, S Thompson	43:125-47

Progress Toward Clinical Application of the Nitric Oxide-Releasing Diazeniumdiolates	LK Keefer	43:585-607
<b>PEPTIDES AND PROTEINS</b>		
Protein Allergenicity Assessment of Foods Produced Through Agricultural Biotechnology	SL Taylor	42:99-112
<b>BIOTRANSFORMATION</b>		
Cytochrome P-450 3A4: Regulation and Role in Drug Metabolism	FP Guengerich	39:1-17
Induction of Cytochrome P4501A1	JP Whitlock Jr	39:103-25
Metabolism of Fluorine-Containing Drugs	BK Park, NR Kitteringham, PM O'Neill	41:443-70
Interindividual Variability in Inhibition and Induction of Cytochrome P450 Enzymes	JH Lin, AYH Lu	41:535-67
Regulation of CYP3A Gene Transcription by the Pregnane X Receptor	B Goodwin, MR Redinbo, SA Kliewer	42:1-23
Human Extrahepatic Cytochromes P450: Function in Xenobiotic Metabolism and Tissue-Selective Chemical Toxicity in the Respiratory and Gastrointestinal Tracts	X Ding, LS Kaminsky	43:149-73
<b>NUCLEIC ACIDS</b>		
Cellular Responses to DNA Damage	CJ Norbury, ID Hickson	41:367-401
Ca <sup>2+</sup> /CaM-Dependent Kinases: From Activation to Function	SS Hook, AR Means	41:471-505
<b>PHARMACOKINETICS/TOXICOKINETICS</b>		
Biochemical, Cellular, and Pharmacological Aspects of the Multidrug Transporter	SV Ambudkar, S Dey, CA Hrycyna, M Ramachandra, I Pastan, MM Gottesman	39:361-97
Mitochondrial Targets of Drug Toxicity	KB Wallace, AA Starkov	40:353-88



## CANCER AND CARCINOGENESIS

Properties and Biological Activities of Thioredoxins	G Powis, WR Montfort	41:261-95
Cancer Chemoprevention Using Natural Vitamin D and Synthetic Analogs	KZ Guyton, TW Kensler, GH Posner	41:421-42
Inhibition of Carcinogenesis by Tea	CS Yang, P Maliakal, X Meng	42:25-54
COX-2: A Target for Colon Cancer Prevention	LJ Marnett, RN DuBois	42:55-80
Glycopeptide Antibiotic Resistance	J Pootoolal, J Neu, GD Wright	42:381-408
Altered DNA Methylation: A Secondary Mechanism Involved in Carcinogenesis	JI Goodman, RE Watson	42:501-25
Signal Transduction-Directed Cancer Treatments	EA Sausville, Y Elsayed, M Monga, G Kim	43:199-231

## CLINICAL THERAPEUTICS

Dual Protease Inhibitor Therapy in HIV-Infected Patients: Pharmacologic Rationale and Clinical Benefits	C Flexner	40:651-76
Pharmacogenomics: Unlocking the Human Genome for Better Drug Therapy	HL McLeod, WE Evans	41:101-21
Antisense Oligonucleotides: Promise and Reality	I Lebedeva, CA Stein	41:403-19
Glycopeptide Antibiotic Resistance	J Pootoolal, J Neu, GD Wright	42:381-408
Complementary and Alternative Therapeutics: Rigorous Research is Needed to Support Claims	JF Kinsel, SE Straus	43:463-84

## DRUG DEVELOPMENT SCIENCE

Parallel Array and Mixture-Based Synthetic Combinatorial Chemistry: Tools for the Next Millennium	RA Houghten	40:273-82
A Novel Means of Drug Delivery: Myoblast-Mediated Gene Therapy and Regulatable Retroviral Vectors	CR Ozawa, ML Springer, HM Blau	40:295-317

Use of Biomarkers and Surrogate Endpoints in Drug Development and Regulatory Decision Making: Criteria, Validation, Strategies	L Lesko, AJ Atkinson Jr.	41:347-66
Molecular Basis of Environmentally Induced Birth Defects	RH Finnell, J Gelineau-van Waes, JD Eudy, TH Rosenquist	42:181-208
Protein Tyrosine Phosphatases: Structure and Function, Substrate Specificity, and Inhibitor Development	Z-Y Zhang	42:209-34
Designing Inhibitors of Cyclin-Dependent Kinases	IR Hardcastle, BT Golding, RJ Griffin	42:325-48
Protein Flexibility and Computer-Aided Drug Design	CF Wong, JA McCammon	43:31-45
Gene Therapy with Viral Vectors	NA Kootstra, IM Verma	43:413-39

## Systems

### IMMUNE SYSTEM/INFLAMMATION

Signal Transduction by Cell Adhesion Receptors and the Cytoskeleton: Functions of Integrins, Cadherins, Selectins, and Immunoglobulin- Superfamily Members	RL Juliano	42:283-323
Structure, Function, and Inhibition of Chemokines	EJ Fernandez, E Lolis	42:469-99
Innate Immune Responses to Microbial Poisons: Discovery and Function of the Toll-Like Receptors	B Beutler	43:609-28

### CENTRAL NERVOUS SYSTEM

Glial Cells in Neurotoxicity Development	M Aschner, JW Allen, HK Kimelberg, RM LoPachin, WJ Streit	39:151-73
Excitatory Amino Acid Transporters: A Family in Flux	RP Seal, SG Amara	39:431-56

Molecular Mechanisms and Regulation of Opioid Receptor Signaling	P-Y Law, YH Wong, HH Loh	40:389-430
Anesthetics and Ion Channels: Molecular Models and Sites of Action	T Yamakura, E Bertaccini, JR Trudell, RA Harris	41:23-51
Interactions Between Monoamines, Glutamate, and GABA in Schizophrenia: New Evidence	A Carlsson, N Waters, S Holm-Waters, J Tedroff, M Nilsson, ML Carlsson	41:237-60
Drug Treatment Effects on Disease Progression	P Chan, N Holford	41:625-59
Molecular Targets of Lithium Action	CJ Phiel, PS Klein	41:789-813
Neurokinin1 Receptor Antagonists as Potential Antidepressants	SC Stout, MJ Owens, CB Nemeroff	41:877-906
Glutamatergic Mechanisms in Schizophrenia	G Tsai, JT Coyle	42:165-79
The Spinal Phospholipase- Cyclooxygenase-Prostanoid Cascade in Nociceptive Processing	CI Svensson, TL Yaksh	42:553-83
Alzheimer's Disease: Molecular Understanding Predicts Amyloid-Based Therapeutics	DJ Selkoe, D Schenk	43:545-84
AUTONOMIC NERVOUS SYSTEM		
$\beta$ -Adrenergic Receptors and Receptor Signaling in Heart Failure	SR Post, HK Hammond, PA Insel	39:343-60
Genetic Variations and Polymorphisms of G Protein-Coupled Receptors: Functional and Therapeutic Implications	BK Rana, T Shiina, PA Insel	41:593-624
CARDIOVASCULAR SYSTEM		
Endothelin System: The Double-Edged Sword in Health and Disease	RM Kedzierski, M Yanagisawa	41:851-76

**K<sup>+</sup> Channel Structure-Activity  
Relationships and Mechanisms of  
Drug-Induced QT Prolongation**

CE Clancy, 43:441-61  
J Kurokawa,  
M Tateyama,  
XHT Wehrens,  
RS Kass

**ENDOCRINE SYSTEM**

**Neurotrophic and Neuroprotective Actions  
of Estrogens and Their Therapeutic  
Implications**

SJ Lee, BS McEwen 41:569-91

**PULMONARY SYSTEM**

**Cytokine Modulators as Novel Therapies  
for Asthma**

PJ Barnes 42:81-98

**Novel Pharmacological Approaches to  
Manage Interstitial Lung Fibrosis in the  
Twenty-First Century**

SN Giri 43:73-95

**Miscellaneous**

**TECHNIQUES**

**The Impact of Genomics-Based  
Technologies on Drug Safety Evaluation  
Challenges for Biomedical Informatics and  
Pharmacogenomics**

JF Waring, RG Ulrich 40:335-52  
RB Altman, TE Klein 42:113-33

**ENVIRONMENTAL TOXICITY**

**The PAS Superfamily: Sensors of  
Environmental and Developmental  
Signals**

Y-Z Gu, 40:519-61  
JB Hogenesch,  
CA Bradfield

**Challenging Dogma: Thresholds for  
Genotoxic Carcinogens? The Case of  
Vinyl Acetate**

JG Hengstler, 43:485-520  
MS Bogdanffy,  
HM Bolt, F Oesch

**Pharmacology and Toxicology in the New Millennium**

**Pharmacokinetic/Pharmacodynamic  
Modeling in Drug Development**

LB Sheiner, 40:67-96  
J-L Steimer

Sequencing the Entire Genomes of Free-Living Organisms: The Foundation of Pharmacology in the New Millenium	S Broder, JC Venter	40:97-132
High-Throughput Screening in Drug Metabolism and Pharmacokinetic Support of Drug Discovery	RE White	40:133-57
Pharmacogenetics of Sulfotransferase	K Nagata, Y Yamazoe	40:159-76
Drug Discovery in the Next Millennium	EH Ohlstein, RR Ruffolo Jr, JD Elliott	40:177-91
The Impact of Genomics on Drug Discovery	C Debouck, B Metcalf	40:193-208
Simulation of Clinical Trials	NHG Holford, HC Kimko, JPR Monteleone, CC Peck	40:209-34

